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Testosterone utilization rates have increased significantly in the last 10 years as 
demonstrated in the United Kingdom, Australia, United States, and by the US  
Department of Defense. Studies show that patients treated with testosterone may not be 
adherent or persistent, and exhibit patterns of restarting, switching, and cycling on 
testosterone therapy.  These medication use behaviors may not be readily detected with 
traditional persistence measures. Managed care organizations and the Department of 
Defense responded to increased testosterone use by implementing prior authorization and 
step therapy programs in order to ensure safe, appropriate use of testosterone. Previous 
testosterone use studies failed to account for the widespread use of these utilization 
programs for testosterone products. The purpose of this study was to evaluate changes in 
testosterone costs, utilization, and medication use behavior before and after the March 1, 
2013 implementation of prior authorization and step therapy programs by the Department 
of Defense. 
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This study included adult men, 18 years of age or older, from the Department of 
Defense Military Health System who received testosterone (other than injectable or 
implant) any time from March 1, 2012 through February 28, 2014. Data were extracted 
from the Department of Defense Pharmacy Data Transaction Service.  
From March 1, 2012 to February 28, 2014, there were 78,623 patients in the 
Department of Defense using the included forms of testosterone. Of those patients, 
26,464 (33.7%)  had testosterone therapy only in the pre-index period, 18,111 (23.0%) 
had prescriptions only in the post-index period, while the remaining 34,048 (43.3%) 
patients had prescriptions both before and after implementation. Testosterone costs 
decreased by $27.5 million in the year following implementation of PA and ST programs.  
During the post-implementation year there were over 8,000 less patients started on 
testosterone treatments, and over 20,000 less testosterone prescriptions dispensed 
compared to the pre-intervention year. In the pre-PA/ST period, adherence (as measured 
by a medication possession ratio of 0.80 or greater) was 55.22%, and in the post-PA/ST 
period adherence was 53.46%. The percent of persistent patients using a 30-day gap, a 
60-day gap and a gap of 1.5 times the previous days supply was calculated. In the pre-
index period this rate was 64%, 75% and 58% respectively; similar to the rates in the 
post-index period (63%, 74% and 56% respectively). In the post-PA/ST period, 19.10% 
of patients switched products, 23.39% restarted therapy, and 18.60% of patients had 
cycles of therapy.  When comparing only the 34,048 patients with prescriptions both 
before and after the PA/ST implementation, the mean gap period pre-index was 47 (SD 
 viii 
69) days but the gap at the point of implementation averaged 94 (SD 100) days (p 
<0.001). 
 Post PA/ST costs were lower, adherence and persistence rates were similar 
(although statistically significantly different) between the two periods, but the gap in 
receiving treatment after the PA/ST was implemented may be cause for concern. This 
study adds to the existing testosterone use literature, specifically how prior authorization 
and step therapy programs influence testosterone use behaviors. The effectiveness and 
impact of testosterone benefit design will inform future Department of Defense formulary 
decisions and deepen understanding of testosterone use behaviors.  
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Chapter 1:  Introduction 
Do you lack energy? Are you feeling grumpy? Do you fall asleep after dinner? 
Are you male? If you answered yes to any of these questions, there is a chance you suffer 
from a treatable condition known as Low-T. Talk to your doctor about Low-T and find 
out how testosterone therapy can help you.1  
 This is the message testosterone manufacturers are sending to American men in 
order to capitalize on a rapidly expanding market for testosterone replacement therapy 
(TRT) or testosterone therapy (TTh). In the United States (US), the testosterone market 
generated $1.9 billion in sales in 2012.2 This market is projected to increase to $5.1 
billion by 2018.3 By 2025, there will be as many as 6.5 million men in the US, 30 to 79 
years old, with symptomatic low testosterone. This is a 38% increase from 2000 
estimates.4 
Testosterone use in the US is increasing, however, testosterone patients may not 
be adherent or persistent, and exhibit patterns of restarting, switching, and cycling not 
detected with traditional persistence measures.5–7 The reasons for this behavior remain 
unknown.5,6 Simultaneously, managed care organizations (MCOs) are using utilization 
management tools such as prior authorization (PA) and step therapy (ST) to manage costs 
and utilization of testosterone. PA and ST strategies may have a negative impact on 
patient adherence, 8 however, the impact of PA and ST on testosterone use behaviors 
specifically has not been studied.  
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 The Department of Defense (DoD) PA and ST programs are unique because all 
patients, even established testosterone users, were required to complete the PA and ST 
process. In addition, a “no-grandfathering” policy for PA and ST programs is atypical for 
the DoD. A review of the results of this deviation from normal conditions may impact 
future policy decisions. Finally, greater understanding of switching, restarting, and 
cycling behaviors is needed. This study expands the understanding of testosterone use 
behaviors by considering the presence of drug benefit controls that may contribute to 
previously documented non-persistence in testosterone use. This retrospective evaluation 
of utilization, costs, and medication use behaviors in testosterone therapy is warranted 
and will contribute significantly to the growing literature on testosterone use and the 
impacts of formulary management tools on medication use behaviors. 
The following literature review explains the rationale and need for an examination of 
how benefit design impacts testosterone use behaviors. First, hypogonadism, or 
testosterone deficiency (TD), the condition known in marketing as “Low-T,” will be 
discussed, followed by a review of TTh and trends in TTh. Next, the behaviors of 
interest, persistence and adherence, as well as switching, restarting, and cycling, will be 
discussed followed by a review of PA and ST. In addition, there will be an examination 
of literature exploring the impacts of benefit design and formulary management on 
medication use behavior. Finally, the study setting, the DoD, and its testosterone 
utilization trends and utilization management tools will be described followed by the 
study methods, results, and discussion..   
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Chapter 2:  Literature Review 
This literature review will discuss the disease state of hypogonadism, testosterone 
therapy (TTh) use, TTh trends, and testosterone use behaviors such as adherence, 
persistence, switching, restarting, and cycling. The economic burden of TTh that drives 
managed care organizations (MCOs) to use prior authorization (PA) and step therapy 
(ST) to manage testosterone utilization will be discussed in detail. Finally, an example of 
testosterone PA and ST programs used by the Department of Defense (DoD) Military 
Health System (MHS) will be presented.  
HYPOGONADISM AND TESTOSTERONE DEFICIENCY 
Hypogonadism is the failure of the testes to produce physiological levels of 
testosterone due to disruption of the hypothalamic-pituitary-testicular axis.9 
Hypogonadism is also known as androgen deficiency, testosterone deficiency syndrome 
(TDS), or low testosterone.10 Patients with TDS experience sleep disturbance (33.0%), 
low physical performance (18.2%), low libido (11.6%), erectile dysfunction (16.3%), 
depressed mood (15.4%), lethargy (11.2%), and osteoporosis or osteoporotic fracture 
(1.4%).4  They may also experience decreased volume of ejaculate, loss of body and 
facial hair, decreased lean body mass, increased body fat, poor concentration, and 
anemia, but the specific frequencies of these symptoms are not known.9,11 These 
symptoms result in significant detriment to quality of life and can impact multiple organ 
systems.12  
According to the Hypogonadism in Males (HIM) study, the prevalence of 
hypogonadism in the United States (US) in men 45 years or older is estimated to be 
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38.7%.11 The prevalence of hypogonadism is 34.0% in ages 45 to 54, 40.2% in ages 55 to 
64, 39.9% in ages 65 to 74, 45.5% in ages 75 to 84, and 50.0% in patients 85 years of age 
and over.11 The Massachusetts Male Aging Study (MMAS) found lower prevalence rates 
of hypogonadism than the HIM. The MMAS found hypogonadism prevalence of 7.1% in 
men ages 48 to 59, 11.5% in ages 60 to 69, and 22.8% in ages 70 to 79.13  
It is important to note, however, that the HIM and the MMAS used different 
definitions of hypogonadism. The HIM defined hypogonadism as evidence of one total 
testosterone level < 300 ng/dL or previous diagnosis of hypogonadism and receiving 
treatment regardless of measured total testosterone levels.11 The MMAS had two methods 
of defining hypogonadism. Both methods required the presence of at least three signs or 
symptoms of hypogonadism. In addition, both methods also required laboratory evidence 
of low testosterone. Method one required one laboratory measure of total testosterone  
<200 ng/dL. Method two required one laboratory measure of total testosterone of 200 - 
400 ng/dL and free testosterone < 8.91 ng/dL.13 
The more strict definition of hypogonadism used in the MMAS explains why the 
prevalence in the MMAS is much lower than the HIM. The two studies do agree, 
however, that the prevalence of hypogonadism increases as age increases. Testosterone 
declines approximately 1% each year after the age of 30.12,14,15 A clinically consequential 
decrease in testosterone due to aging is known as androgen deficiency of the aging male 
(ADAM), andropause, or late onset hypogonadism (LOH). While an exact total 
testosterone level for diagnosis is not specified, the Endocrine Society states that the 
lower limit for the normal range established by the reference laboratory should be used. 
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This value is usually around 300 ng/dL.10 Diagnosis criteria are discussed further in the 
diagnosis section of this chapter.  
The HIM explored prevalence by age as well as by comorbidities. For example, the 
prevalence of hypogonadism is 52.4% in obese patients and 50.0% in patients with 
diabetes.11 Cardiovascular comorbidities such as obesity, metabolic syndrome, and type 
two diabetes mellitus are associated with low testosterone.16 The burden of these 
comorbidities is thought to be the major cost driver for patients with low testosterone.17    
One study using the Ingenix Employer Solutions database, which represents 55 large 
self-insured American companies, sought to compare direct and indirect healthcare costs 
for men with a diagnosis of hypogonadism and at least one testosterone prescription 
against a matched cohort without hypogonadism. In the study population of 4,269 men 
ages 35 to 64, the men with hypogonadism had higher rates of hyperlipidemia (50.2% vs. 
25.3%), hypertension (37.7% vs. 21.1%), back or neck pain (32.0% vs. 15.7%), and 
human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) 
(7.1% vs. 0.3%) (all  p<0.0001). Even after adjusting for higher comorbidity rates in the 
hypogonadism group, the hypogonadism group had significantly higher mean direct costs 
during the study period compared to the control group ($9,291 [$10,202] vs. $5,248 
[$5,762], p < 0.0001) and higher indirect costs ($2,729 [$2,111] vs. $1,840 [$1,423], p < 
0.001) than the control group.17 
Additionally, low testosterone may increase mortality. In a population of Veteran’s 
Health Administration (VHA) men forty years old or older, testosterone levels less than 
250 ng/dL were associated with increased risk of mortality (1.68, 95% CI, 1.14-2.48, p < 
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0.001) compared to men with normal testosterone.18 A follow-up study conducted in a 
national VHA population compared mortality in men with hypogonadism treated with 
testosterone replacement therapy (TRT) to those without treatment. After adjusting for 
age, body mass index (BMI), testosterone level, medical morbidity, diabetes, and 
coronary heart disease, the overall mortality for treated men was associated with a 
decreased risk of mortality (0.61, 95%  CI, 0.42 - 0.88).19 In general, low testosterone is 
associated with increased morbidity and mortality, however, this association varies by the 
type of hypogonadism. 
Types of Hypogonadism 
There are three categories of hypogonadism: primary testicular failure, secondary 
testicular failure, and combined primary and secondary. Another preferred terminology is 
testosterone deficiency (TD). Each type has different causes and consequences. Primary 
testicular failure is caused by abnormalities of the hypothalamic-pituitary-thyroid axis at 
the testicular level and results in decreased testosterone levels, spermatogenesis 
impairment, and elevated gonadotropin levels.10 Secondary hypogonadism occurs in 
defects of the central hypothalamus or pituitary axis which cause testicular failure and 
results in decreased testosterone levels, spermatogenesis impairment, and low to low-
normal gonadotropin levels.10 The third type, combined primary and secondary 
hypogonadism, results in low testosterone, impaired spermatogenesis, and variable 
gonadotropin levels.10  
Combined primary and secondary hypogonadism occurs in hemochromatosis, sickle 
cell disease, thalassemia, glucocorticoid treatment, alcoholism, dosage sensitive sex-
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reversal adrenal hypoplasia congenital critical region on the X-chromosome gene 1 
(DAX-1) mutations, and in older men.10 The decline in testosterone related to age is 
believed to result from defects in both testicular function and hypothalamic-pituitary 
function and therefore this mixed type of hypogonadism is generally the type experienced 
by aging men.10  
Diagnosis 
The Endocrine Society suggests making a diagnosis of androgen deficiency in men 
with consistent symptoms or signs of low testosterone and “unequivocally low serum 
testosterone levels.” The Endocrine Society recommends a morning total testosterone test 
followed by a confirmatory morning test.10 While an exact total testosterone level for 
diagnosis is not specified, the Endocrine Society states that the lower limit for the normal 
range established by the reference laboratory should be used. This value is usually around 
300 ng/dL.10 
According to the Endocrine Society, making a hypogonadism diagnosis can be 
difficult. First, signs and symptoms are nonspecific, and they are confounded by age, 
comorbidities, severity, and duration of deficiency. Additionally, laboratory measurement 
of testosterone presents many challenges. Testosterone levels vary with circadian cycles; 
therefore, testosterone laboratory testing should be conducted in the morning, but this 
recommendation is frequently not followed.10,20 Complicating laboratory values further, 
there are multiple ways to measure testosterone such as free, bound, and total levels.10 
The guidelines are clear, however, on which patients should be treated with TRT.10  
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Treatment 
The Endocrine Society recommends TRT for symptomatic men with classic 
androgen deficiency symptoms and low testosterone levels. The goal of treatment is to 
improve sexual function, improve sense of well-being, increase bone mineral density, 
induce or maintain secondary sex characteristics, improve fat free mass, and increase 
muscle strength.10 Objectively, the success of TRT is determined by measuring 
testosterone levels pre and post treatment. The Endocrine Society recommends 
monitoring testosterone levels three to six months after initiation with target testosterone 
levels that vary depending on the testosterone form used. In general, a testosterone level 
between 350 and 750 ng/dL, which is considered a mid- to normal- range for healthy, 
young men is recommended.10 
The Endocrine Society’s 2010 clinical practice guidelines for androgen deficiency 
do not state a specific testosterone threshold for LOH treatment. The panel of authors 
could not agree on a threshold recommendation for TRT in older men – as a decline in 
testosterone is expected as men age. Instead, the panel recommended that additional 
research should be conducted. Panelists did agree, however, that older men should be 
treated depending on the severity of their symptoms.10 
There are many forms of TRT available. According to Lexi-comp, as of June 
2015, testosterone forms available in the United States (US) include long-acting 
injectable, transdermal gel, transdermal solution, transdermal cream, transdermal 
ointment, transdermal patches, nasal gel, buccal adhesive tablets, and pellet implants.21 
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The particular product selected depends on patient preference, pharmacokinetics, 
treatment burden, and cost.10  
One of the most popular testosterone products is Androgel. There are two 
strengths of Androgel available. The newer product of the two, Androgel 1.62%, requires 
the application of a smaller volume of gel for the starting dose than Androgel 1%, the 
older product. Androgel 1.62% is available in packets as well as a pump whereas the 1% 
is only available in packets.22,23 Testosterone 1% gel was approved in a generic form in 
2012. Androgel 1.62% became available in 2011.24 
Each particular testosterone product has a recommended starting dose, 
maintenance dose, and dosing range that vary depending on dosage form and 
concentration.22,23,25–28 Schoenfeld et al. categorized doses as low (< 50 mg/day), standard 
(50 mg/day), and high (> 50 mg/day) for Testim and Androgel. Other studies described 
dose as a proportion of recommended starting dose in order to standardize the daily dose 
across products. The dose as a proportion of recommended starting dose per day was 
calculated by first calculating the total number of milligrams of testosterone dispensed 
divided by the number of days supply for each prescription. This established the 
milligrams of testosterone per patient per day. The number of calculated milligrams of 
testosterone per day is then divided by the recommended number of milligrams 
recommended by the manufacturer as the starting dose per day to establish a proportion 
of the recommended starting dose.29 The recommended starting dose is available for each 
individual product in the prescribing information.22,23,25–28 
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Known adverse events associated with testosterone include erythrocytosis, acne 
and oily skin, detection of subclinical prostate cancer, growth of metastatic prostate 
cancer, and reduced sperm production and fertility (without the addition of gonadotropin-
releasing hormones).10 In addition, each formulation has specific adverse events such as 
skin reactions for topical products (17% - 37%)21, gum irritation for buccal products 
(9.2%)30, and injection site irritation for injectable products (5%).10 The impact of these 
adverse events and patient perception of treatment success can be measured using patient 
reported outcomes (PROs). 
The subjective measure of TRT success, symptom relief, is best measured using 
PROs such as health related quality of life (HRQoL) measures.31 Many instruments have 
been developed to measure HRQoL in men with LOH such as the Aging Males’ 
Symptoms (AMS) scale, MMAS Questionnaire, and ADAM scale.10,31 Each instrument 
varies in specificity to hypogonadism, objective, domains covered, reliability, validity, 
and responsiveness. The use of HRQoL studies for TRT captures how patients perceive 
the effectiveness of TRT, which may influence medication use behavior in this 
population. 
Moore et al. used the AMS to assess treatment effects of testosterone after 12 
weeks of TRT in Germany. They found that patients with the worst HRQoL (highest 
AMS score) before treatment experienced the greatest improvement in HRQoL (decrease 
in AMS score) with treatment. On average, patients experienced a 31.8% improvement 
overall in AMS scores.32  
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Behre et al. found that in British patients with low-normal testosterone, HRQoL 
as measured by the AMS improved with 1% testosterone gel treatment after six months 
compared to placebo. However, after 12 months there was no additional improvement in 
HRQoL.33 This raises the question of whether topical testosterone produces sustained 
symptom relief which would encourage patients to continue therapy. The length of time 
needed to experience symptom relief may also influence TRT use behaviors.  
In LOH, the effects of testosterone treatment are not immediately perceptible. 
Many effects are detectable after three weeks of treatment, but may take longer and vary 
widely from patient to patient.34 Erection and ejaculation changes take up to six months 
for detectable differences.34 In addition, many of the improvements from testosterone 
treatment plateau with continued use.34 Symptoms related to HRQoL, such as sexual 
interest and improved mood, require three to six weeks to detect changes and plateau at 
six weeks and 18 to 30 weeks, respectively. Changes in fat mass, lean body mass, and 
muscle strength stabilize after six to 12 months.34 Patients may struggle to see the 
benefits of treatment in a meaningful way and may become impatient and discontinue 
treatment due to lack of perceived benefits or sustained benefits. Additionally, 
continuously declining testosterone may present as a worsening of symptoms.15 Another 
possible reason to reconsider TRT is the increasing safety concerns associated with TRT. 
TESTOSTERONE SAFETY 
While there is evidence of the benefits of testosterone therapy, the risks of 
testosterone treatment are a highly debated topic. Testosterone is contraindicated in men 
with prostate or breast cancer, men with a palpable prostate nodule or induration, or 
 12 
prostate-specific antigen (PSA) greater than 3 ng/dL due to the association of testosterone 
therapy with an elevated risk of prostate events such as cancer and benign prostatic 
hyperplasia (BPH).9 In addition to potential prostate problems, testosterone has been 
linked to cardiovascular risks including heart attack, stroke, and blood clots.35,36 
The risks of cardiovascular events in TRT are controversial. In a retrospective 
study of a national cohort of men in the VHA system with testosterone levels < 300 
ng/dL who underwent coronary angiography from 2005 – 2011, Vigen et al. aimed to 
assess the association between testosterone therapy and all-cause mortality, myocardial 
infarction (MI), and stroke. Initiation of testosterone therapy was defined as filling one 
prescription for testosterone gel, patch, or injection following coronary angiography. 
Therapy was assumed to be continued until an outcome event occurred or the end of the 
follow-up period. Patients were categorized in the testosterone treatment group after just 
one prescription.  
Overall, the patients on testosterone therapy had an increased risk of adverse 
outcomes such as mortality, MI, and stroke. Of 8,709 men with testosterone lower than 
300 ng/dL, 1,223 patients started testosterone therapy after a median of 531 days after 
coronary angiography. The Kaplan-Meier absolute risk difference of having one of the 
outcome events between the no testosterone group and the testosterone group was 5.8% 
(95% CI, -1.4% to 13.1%). After adjusting for presence of coronary artery disease, 
testosterone use was associated with increased risk of an adverse outcome (hazard ratio, 
1.29, 95% CI, 1.04 to 1.58).  
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Of the 1,223 patients that initiated testosterone therapy, 17.6% only filled one 
prescription. Of the patients that filled more than one prescription, the mean number of 
days from the first fill to the last fill was 376 days. Of those prescribed testosterone, 60% 
had at least one testosterone level checked after testosterone initiation, and the mean level 
at that check was 332.2 ng/dL.37  
While this does raise questions about a possible relationship between testosterone 
and cardiovascular events, the assumption that one prescription constitutes adequate 
exposure to testosterone and therefore, a long enough exposure to be associated with 
adverse outcomes is a tenuous assumption. Of the patients that filled more than one 
prescription, it is not known if the patient used testosterone continuously from the first 
fill to the last fill. The definition of the testosterone group may have been too broad to 
indicate testosterone therapy is associated with increased risk of adverse outcomes.  
This study prompted multiple responses. One response from an endocrinologist 
stated that the Vigen et al. study contributed to the mounting evidence of a signal of 
cardiovascular risk with testosterone. However, without large, long-term, randomized 
trials to conclusively assess long-term benefits and risks of testosterone therapy, this 
study alone is not enough to show a significant association with increased risk of 
cardiovascular events. In addition, the Vigen et al. study had limited generalizability 
because of the uniqueness and specificity of the VHA population.38 Another issue that 
erodes the quality of this study is the necessity to publish a correction to the text and 
figures due to misclassification of patients and publishing of incorrect data.39 
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In men 65 years and older, Finkle et al. found an increased rate of MI up to ninety 
days after filling a prescription for testosterone, compared to the twelve months prior to 
initiating testosterone. Comparing the incidence of MI after testosterone to before 
testosterone, the rate ratio for MI was 2.19 (95% CI, 1.27 to 3.77).40 Critics of this study 
felt that the reported excess risk is clinically insignificant and pointed to the possibility 
that patients newly diagnosed with low testosterone are at risk for cardiovascular events, 
and that the risk of events may have diminished outside of the 90-day follow-up period.41  
Consequently, cardiovascular risks are not known, but the Food and Drug 
Administration (FDA) found this trend compelling enough to issue a safety 
communication alert for testosterone products and the risk for stroke, heart attack, and 
death.42 The FDA also issued a warning about the potential for blood clots.35 Lastly, 
concerns of topical product transfer to women and children prompted the FDA to require 
a Risk Evaluation and Mitigation Strategy Medication Guide, as well as label changes, 
reflecting this risk.36  
In September 2014, The Bone, Reproductive and Urologic Drugs Advisory 
Committee of the Drug Safety and Risk Management Advisory Committee of the FDA 
voted to further restrict FDA indications for testosterone in order to reduce the number of 
patients using testosterone for “age-related” purposes rather than previously approved 
indications.43 Furthermore, the committee recommended that the FDA not approve an 
application from Clarus Therapeutics for a new oral testosterone product named 
Rextoro.44 The committee expressed concerns that an oral form of testosterone may be 
susceptible to abuse and emphasized general concerns of testosterone safety.44 
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In light of ongoing controversy surrounding testosterone safety, there is a clear 
need for conclusive studies about testosterone safety. In the absence of large, 
randomized, controlled studies assessing testosterone benefits and risks, the trend of 
increasing testosterone use is concerning. Millions of men are in what has been called, “A 
mass, uncontrolled experiment that invites men to expose themselves to the harms of a 
treatment unlikely to fix problems that may be wholly unrelated to testosterone levels.”45 
The extent of this increase in testosterone utilization is discussed further in the following 
section. 
TESTOSTERONE TRENDS 
It is projected that the US will have 25 million men with LOH by 2025.46 
Testosterone replacement manufacturers are working hard to capture this market. 
AbbVie, the makers of Androgel, launched a campaign known as “Is it Low-T?” aimed to 
raise awareness of low testosterone symptoms. AbbVie is especially focused on aging 
men experiencing symptoms of low testosterone due to routine aging.  
The “Low-T” campaign uses a modified form of the AMS as a screening tool for 
patients and spouses to encourage them to talk to their doctor about TRT. The AMS is 
not designed to be a screening tool.47 In addition, the Endocrine Society recommends 
against screening for androgen deficiency in the general population due to lack of data on 
the how available screening tools perform and because the benefits and adverse 
consequences of TRT are unclear.10 Low-T “quizzes” lack specificity for low 
testosterone. A “positive” quiz may trigger a patient to seek treatment for low 
testosterone.45 
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Through population-wide disease awareness marketing, AbbVie successfully 
increased Androgel market share by 19% from November 1, 2011 through October 31, 
2012 resulting in $1.37 billion in sales. Androgel represented 72% of the $1.9 billion US 
testosterone market during that time.2 There are many skeptics of this marketing activity, 
and many see these campaigns as the commercialization of a disease.45  
Even in countries that prohibit direct-to-consumer advertising, the use of 
testosterone is growing. In the United Kingdom (UK), testosterone prescribing increased 
90% in 10 years from 157,602 prescriptions in 2001 to 298,134 in 2010.48 In Australia, 
testosterone prescribing doubled from 1992 to 2010, driving annual expenditures up nine-
fold to $12.7 million per year.49  
The VHA, which authors considered “relatively insulated from marketing,” 
exhibited increasing rates of exogenous testosterone use from October 1, 2010 through 
September 30, 2011 in men who did not test positive for HIV and with at least one 
outpatient visit or hospitalization in the VHA system.50 Researchers found that 1.67% of 
the men included in the study received exogenous testosterone from a VHA pharmacy 
during the study period. Rates of testosterone use varied from 0.3% to 3.7% depending 
on the VHA site. Injectable, topical, and oral capsules of testosterone were included.  
Total spending on those testosterone products during that time period was $20.9 
million. The authors emphasized that rates of utilization varied widely between each 
VHA site and there may have been high rates of off-label prescribing of testosterone.50 
The authors recognized that their findings bring to light the need for standardized 
practices VHA wide that are consistent with existing evidence and guidelines.50 As of 
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November 2014, the Veteran’s Affairs (VA)/DoD Evidence-Based Practice Guideline 
Work Group (EBPWG) has not established a clinical practice guideline for testosterone 
use.51 The authors mentioned that they plan to conduct a follow-up study examining 
patient-level and site-level predictors of testosterone use.50  
Even in health care systems with standardized guidelines, there are concerning 
trends in testosterone use. In Saskatchewan, Canada, from 1976 to 2008, Hall et al. 
identified 11,521 testosterone users who received a median of two prescriptions for 
testosterone.52 In 1976 the number of testosterone users per 1,000 men in the 
Saskatchewan population was 1.6. From 1994 to 1999 the annual rate of use increased on 
average by 24.7%, peaking at 4.2 testosterone users per 1,000 men in the Saskatchewan 
population. 45 
Rates of testosterone use declined from 2002 to 2008, possibly due to the new 
availability of phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, during that 
time.52 Until 1999, androgen products were prescribed for erectile dysfunction. When 
PDE-5 inhibitors became available, patients may have switched to them instead of using 
testosterone.52 Also, in 2006, Health Canada informed testosterone manufacturers that 
testosterone could not be indicated for general purposes such as “andropause.” This 
change may have contributed to the decrease in testosterone use from 2006 to 2008.52 
Differences in health care delivery between Canada and the US make this study difficult 
to generalize to US patients. 
Specific studies in the US show dramatic increases in testosterone use starting in 
2001. Testosterone trends were studied using a large, commercially insured population 
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via Clinformatics DataMart (CDM). Prevalence of testosterone use in men increased 
more than three-fold from 0.81% in 2001 to 2.91% in 2011. Use of topical testosterone 
gel increased five-fold. The median number of days the subjects had a supply of 
testosterone available in the first twelve months following initiation of therapy was 150 
days. Approximately 18.6% of incident users only filled one prescription.53 
The proportion of days patients had a supply of testosterone in the first 12 months 
following initiation was only 0.41.53 This raises concerns that men initiating testosterone 
may not be adherent with the prescribed regimen. Additional studies that specifically 
describe testosterone medication use behaviors such as persistence and adherence are 
available. Before reviewing those studies, the next section will examine persistence and 
adherence in general. 
MEDICATION USE BEHAVIORS: ADHERENCE AND PERSISTENCE 
Adherence 
Two concepts are generally used to describe medication use behaviors, adherence 
and persistence. Adherence measures how a patient complies with, or adheres to, a 
prescribed medication regimen.54 The full benefit of medications can only occur if 
patients follow their medication regimen reasonably closely.54 Therefore, it is important 
to understand how a patient adheres to a medication regimen in order to realize benefits 
from the therapy. 
The specific information captured by adherence measures varies by measurement 
type. For example, with indirect measures captured by prescription claims in a database, 
it is not known if the patient took the correct dose at the correct time. Other measures 
 19 
such as directly observing therapy through blood markers demonstrates the drug was 
taken but the exact amount and schedule is still not known.54 It is common to use 
prescription claims data to assess patient adherence. If a patient has a paid claim for a 
prescription, it is assumed that the patient is adherent to the medication regimen. Of the 
claims-based methods of measuring adherence, the two most commonly used are 
medication possession ratio (MPR) and proportion of days covered (PDC).55 
 The MPR is the sum of the days supply for all claims during a defined period of 
time divided by the number of days in the period.56 There are multiple ways of applying 
this measure to claims, and therefore multiple MPR methodologies. Patients with an 
MPR of 80% or higher are generally considered adherent.57  
PDC tends to be more conservative than MPR when used for multiple 
medications at one time, switches between drugs, or therapeutic duplication for a single 
condition.58  PDC is the proportion of the number of days a patient has the medication 
available in specified period.58  PDC always ranges from zero to one because it avoids 
double-counting covered days. It can also be dichotomized similarly to MPR.59 Each day 
is assessed for the presence or absence of the medication in question and a binary 
measure of presence or absence is determined.58 
Assessing adherence using claims data has many strengths.56 Using claims 
information avoids the “Hawthorne Effect” in which patients behave differently because 
they know they are being observed.56  In addition, evaluating adherence using claims is 
inexpensive compared to other methods of adherence assessment. There are, however, 
limitations to using claims data measures. It is possible for each method of assessment to 
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yield a different result.56 In addition, there is an underlying assumption that when a 
prescription is filled the patient is taking the medication as prescribed. 
Persistence 
Persistence aims to capture “the duration of time from initiation to discontinuation 
of therapy.”60 Persistence as a continuous measure is the number of days from initiation 
of therapy (or a certain point of time in chronic treatment) to a point in time defined by 
the end of the observation period or until the patient exceeds the permissible gap, 
whichever comes first.61 A permissible gap reflects the amount of time during which a 
patient may not fill or refill a prescription but is still considered to be using the therapy.  
If a patient exceeds the permissible gap between refills, the patient is considered 
to be non-persistent. The permissible gap depends on the specific therapy and situation 
being studied but gaps such as 30 days, 60 days, or 1.5 times the previous days supply 
have been used.55,60 Persistence can also be reported as a dichotomous measure. Patients 
persistent without an unacceptable gap in therapy are classified as persistent and patients 
with an unacceptable gap are classified as non-persistent.  
Factors Influencing Medication Use Behaviors 
Patient, provider, and system-wide factors all influence medication adherence.54 
Patient-level barriers to adherence are common. The number one reason patients cite as a 
reason for non-adherence is forgetfulness, which is cited by 30% of non-adherent 
patients. Having other priorities (16%), making a decision to omit doses (11%), lack of 
information (9%), and emotional factors (7%) are other patient reasons for non-
adherence.54  
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 Patients who do not understand the disease state, benefits and risks of treatment, 
and proper use of the medication are less likely to be adherent.54 The complexity of the 
drug regimen is inversely related to adherence. In other words, the more complicated the 
regimen, such as frequency of dosing, the less likely the patient is to be adherent.54 
Physicians can also contribute to non-adherence. When providers are not familiar with 
drug cost or the individual patient’s pharmacy benefits, they may chose medications that 
the patient will have difficulty accessing or affording.54  
The patient’s experience within the health care system impacts adherence. When 
patients miss appointments, receive poor treatment from clinical staff, are switched to a 
new drug due to formulary restrictions, cannot access the pharmacy, or cannot afford the 
medication, adherence tends to decrease.54  
Motheral’s 2011 review of the ST literature raises questions about the impact of 
ST on multiple types of outcomes. Motheral’s review found a gap in the literature 
regarding the evaluation of the ST effect on medication discontinuation and 
appropriateness of use.62 Similarly, in 2014 Seabury et al. called for further research on 
the factors driving non-adherence, including cost sharing and financial disincentives for 
patients that may be driving non-adherent behavior.63 Benefit design may play an 
important role in understanding medication use behaviors, but additional studies are 
needed to explore this relationship. 
Medication adherence is known to have significant financial impact on patients, 
manufacturers, and health care payers. From a patient perspective, adherence may mean 
better disease control, increased adverse events, or higher out-of-pocket costs. According 
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to Capgemini Consulting, pharmaceutical manufacturers lose $188 billion in annual 
revenues in the US due to patient non-adherence. For health care payers, adherence 
means spending more on medications; however, payers are likely to realize savings 
related to improved disease control and ideally lowered overall health care costs.64 
Adherence and persistence are unique when it comes to testosterone use. The 
following section examines literature that specifically addresses testosterone use 
behaviors. 
ADHERENCE, PERSISTENCE, AND OTHER BEHAVIORS IN TESTOSTERONE 
REPLACEMENT THERAPY 
The literature on testosterone use behaviors continues to expand and gain interest. 
An FDA Advisory Panel noted the typical length of treatment for testosterone products 
has been reported to be between three and four months.65 The panel noted that this is a 
major characteristic of the overall pattern of testosterone use in the US.65 This conclusion 
is backed by a series of studies addressing testosterone use behaviors.5,53  
One of the earliest examinations of testosterone therapy duration was a 
retrospective chart review that identified 127 men with testosterone deficiency initiating 
treatment from June 2000 to 2001. The authors did not state the location of the study. 
Injectable testosterone, Androgel 1%, and Androderm were included. Patients had 
follow-up appointments with physicians after three months of therapy. At that time, 
patients who were not responding to treatment were encouraged to quit therapy. After 
three months, 30% of the original 127 men discontinued treatment. After 12 months of 
therapy, 63% of the original 127 remained on therapy. Of those, 70% reported symptom 
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resolution.6 Therefore, of the original 127, 44% experienced symptom resolution after 12 
months of therapy. It is unknown at what point in time between the initial physician 
follow-up at three months and the final follow-up at 12 months patients had changes in 
symptoms. This study does not describe traditional measures of adherence or persistence, 
has a very small number of participants, and omits nine months of potentially important 
observations. The description of the treatment setting lacks details, adding to the 
difficulties of interpreting this study.6 
Baillargeon et al. examined testosterone trends in a population of 10,739,815 men 
identified from CDM data from 2001 to 2011. The authors found that the median number 
of days covered by androgen prescriptions following treatment initiation in 2010 was 150 
days. In initiating patients, about 18.63% filled only one prescription for a maximum of a 
30-day supply. CDM is comprised of commercially insured individuals in the US, and 
includes prescription claims data.53 It encompasses multiple MCOs and plan types. The 
utilization management tools used, such as PA or ST, for testosterone products were not 
investigated in this study, but could have contributed to therapy discontinuation and the 
number of patients that only filled one prescription if a PA or ST was initiated during the 
study period. 
 Recognizing the lack of information about TRT adherence, Schoenfeld et al. 
examined 15,435 hypogonadal men from the Thomson Reuters MarketScan Database for 
adherence and persistence patterns for the year 2009. The authors defined adherence 
using an MPR of greater than 0.8. They defined persistence as “the duration of therapy 
from the index date to the earliest of the following events: end date of the last 
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prescription, date of the first gap of more than 30 days between prescriptions, or end of 
the study period (12 months).”5 The authors also examined dose escalation, switching, 
restarting, continuation, and discontinuation.  
Continuation was defined as having index drug refills throughout the study period 
with no gaps between refills of greater than or equal to 30 days. Discontinuation was 
defined as not having a refill of the index drug within 30 days of the last day of the most 
recent fill of the index drug. Switching was defined as filling a prescription for a 
medication other than the previous agent (including brand or administration route) 
without refilling the previous agent. Restarting was defined as a refill of the index drug 
after a discontinuation of more than 30 days.5 
They found that 75% of the patients initiating testosterone therapy were using 
Androgel (concentration not specified in study). Adherence rates (percentage of patients 
with MPR >0.80) overall were low (32.7% for specific hypogonadism and 29.4% for 
nonspecific hypogonadism). The overall average MPR was 56% over six months. 
Specific and nonspecific hypogonadism groups used testosterone for a short average 
length of therapy (146 days for specific hypogonadism and 137 days for nonspecific 
hypogonadism). There was no difference in length of therapy by age group, initial dose, 
or product type. Termination and switching patterns appeared to be the same for 
Androgel and Testim.5 
Overall, 66.4% of patients discontinued therapy after two months. Of those who 
discontinued, approximately 50% restarted. Those who restarted within one to two 
months of discontinuing discontinued again at a mean of 32 days. Those who restarted 
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within six to eight months of discontinuing discontinued again at a mean of 207 days. 
Only 5% of men who restarted switched to another product.5 
The authors concluded that age does not predict adherence for Androgel or 
Testim. Additionally, the authors speculated that the low switching rate may be 
attributable to patient satisfaction with their current product. The patient may perceive 
greater efficacy from their current product, be more familiar with product use, and may 
have had a prescription with refills already at the pharmacy which would make refilling 
that product more convenient.5  
The authors described the patient population represented by MarketScan, but did 
not take into consideration that the benefit design for each plan represented in 
MarketScan is different. This level of detail is not possible with large databases, such as 
MarketScan, that represent multiple insurers. In this study, the patients were Medicare-
insured, US patients, but the specific benefit design for testosterone products is unknown. 
Therefore, it is possible that benefit design, such as PA or ST, impacted patient behavior 
and may partially explain restarting behaviors if therapy was disrupted by the PA or ST 
process. The fact that 50% of men restarted after discontinuation highlights the need for 
further investigation of medication use behaviors beyond adherence and persistence.5 
Another MarketScan study was conducted using patients who received their first 
TRT prescription during 2009. Patients were followed for 12 to 30 months following 
initiation. There were 15,435 men identified on topical treatment and 517 on short-lasting 
injectable testosterone.  
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Several treatment patterns were identified. Interruption was defined as not having 
a refill within 30 days of the last prescription. Of those with interruptions, patients may 
have restarted therapy after 30 days or more or discontinued therapy entirely. If patients 
restarted more than once, they were deemed cyclic users. If patients switched products 
but did not have a gap of more than 30 days they were considered to be on continuous 
therapy.7 A subgroup analysis further divided patients into long-term users (more than 12 
months of continuous treatment), complete discontinuation, and cyclic users. Age, 
physician specialty, copays, diagnosis, comorbidities, and use of PDE-5 inhibitors were 
evaluated. 
 At three months after initiation, 54% of topical patients and 37% of injectable 
patients were still using TRT. One year after initiation of therapy, only 18% of topical 
and 5% of injectable patients were considered to have continuous treatment.  
Cyclical patients made up the majority of subjects (60% for topical and 64% of 
injectable). These are the users that restarted therapy at least 30 days after the end of the 
last day of the previous prescription, possibly multiple times. After each gap greater than 
30 days after the end of the previous prescription, 40-50% of cyclical transitioned to 
“discontinued” status. In the sub-analysis, the authors were not able to detect meaningful 
differences between long-term, short-term, and cyclic users by age, physician specialty, 
copays, diagnosis, comorbidities, and use of PDE-5 inhibitors before and during 
testosterone therapy.7 
Similarities between the injectable and topical forms in terms of therapy 
continuation suggest that treatment patterns with testosterone are disease driven rather 
 27 
than product driven. The authors recommend educating patients on realistic expectations 
of treatment and monitoring of testosterone levels to encourage patients to continue 
therapy.7 
The authors recognize that their measure of interruption may have been too 
strict.38 Because of not taking into account the previous prescriptions’ days supply, and 
using 30 days as the threshold for interruption, the adherence rates may be artificially 
low. A sensitivity analysis using different gaps such as 1.5 times previous days supply 
would strengthen this study. The concept of cyclical treatment recognizes that 
testosterone behavior goes beyond measuring restarting. Most of the patients in this study 
exhibited some type of cycling or restarting behavior that would not be detected using 
traditional adherence and persistence measures. 
Puenpatom et al. conducted one study evaluating adherence and switching and 
another study evaluating persistence of TRT in the US from 2005 to 2011. Both studies 
used MarketScan data and included men, ages 18 to 65, that initiated TRT during the 
study period and had a hypogonadism diagnosis. Subjects were required to have a 
minimum of six months continuous enrollment before and 12 months after the TRT index 
date. In the adherence study, MPR and PDC were both measured. In the persistence 
study, the percentage of patients who remained persistent with their index therapy was 
measured using the product-limit method.66,67 
The adherence study identified 106,039 patients. The mean MPR and PDC were 
0.47 and 0.44 respectively. The overall adherence rate was 21.4%. About 13% of patients 
switched to a different testosterone product during the study.66 Patients receiving pellets 
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had the highest PDC (0.59), followed by those receiving gels (0.43), short-acting 
injections (0.39), buccal (0.28) and patches (0.27). Statistical significance was reported 
(p<0.001), but the type of test used was not.66 
In the persistence study, the authors identified 140,098 patients. About half of the 
patients were persistent at four months of therapy, 36.9% at six months, 24.4% at 12 
months, 13.6% at 24 months, and 8.9% at 36 months. After 12 months, 25% of patients 
using gel or pellet forms of TRT continued on their initial therapy. Of patients using 
short-acting injections, 17.1% continued on initial therapy and of patients using a patch, 
7.8% continued on initial therapy.66 
Layton et al. compared testosterone dosage forms to determine if patches, 
injections, and gels have similar associations with cardiovascular events. As part of the 
study, authors measured treatment duration days. From January 1, 2000 to December 31, 
2012, the authors identified 544,115 testosterone initiators from the MarketScan and 
Medicare databases in the US, and Clinical Practice Research Datalink and general 
practitioner records in the UK. The mean treatment duration for gel was 122 (SD 112) 
days, injection was 105 (SD 104) days, and patches were 96 (SD 91) days.68 Injections 
were associated with a greater risk of cardiovascular events (1.26, 1.18-1.35), 
hospitalizations (1.16, 1.13-1.19), and deaths (1.34, 1.15-1.56) compared with gels in 
hazard ratio analysis with a 95% confidence interval. Injections did not have a higher risk 
of venous thromboembolism (VTE) compared to gels (0.92, 0.76-1.11). Gels and patches 
had similar risks of cardiovascular events (1.10, 0.94-1.29), hospitalizations (1.04, 1.00-
1.08), death (1.02, 0.77-1.33), and VTE (1.08, 0.79-1.47). If in fact injections are 
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associated with higher risks of adverse events, long-term use of injections may be 
undesirable and persistent use unadvisable. 
Testosterone level monitoring is recommended at baseline and after three to six 
months of therapy. Follow-up monitoring allows for dose adjustment in order to reach 
appropriate testosterone level goals.10 Muram et al. evaluated dose titration and 
testosterone level assessments in patients using topical testosterone. Using OptumHelath 
Reporting and Insights claims data, Muram et al. identified 4,416 men that started a 
topical testosterone agent from January 1, 2011 to March 31, 2012. Inclusion criteria 
required 12 months of continuous enrollment and at least six months of study observation 
time. Patients were required to have an initial dose of testosterone at the recommended 
starting dose. Outcome measures included maintenance dose attainment month, time to 
stopping index product, or time to a claim for a non-index product, and proportion of 
patients with a testosterone assay or hypogonadism diagnosis in the study period. The 
recommended starting doses per day for the included products are Axiron 60 mg, 
Androgel 1% 50 mg, Androgel 1.62% 40.5 mg, Fortesta 40 mg, and Testim 50 mg.29 
These recommended starting doses are consistent with the manufacturers’ prescribing 
information.22,23,25,27,69 Maintenance dose was attained in month four at 115.2% of the 
recommended starting dose. Baseline testosterone levels were obtained in 46% of 
patients. The patients with a baseline testosterone level were more likely to have a 
hypogonadism diagnosis in the first six months following the index date (44.7% vs. 
35.8%, p < 0.001) and to have a follow-up testosterone level (50.6% vs. 28.3%, p < 
0.001). During the six months after initiation, 63.2% of patients stopped refilling the 
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index product or filled a prescription for a non-index product. There were no significant 
differences in the time to stop refilling index treatment or filling a non-index product 
between the groups that either had a baseline testosterone assay (1229, 64.5%) and those 
that did not (1391, 62.1%)(p = 0.113). The mean time to stopping refills of an index 
product or filling a non-index product was 72.7 days in patients with a baseline essay and 
70.9 in those without (p = 0.477).  
Overall, 43.4% of all patients stopped refilling the index product. Patients with a 
baseline assay were significantly less likely to stop filling the index product (41.3% vs. 
45.2%, p < 0.001) and more likely to continue treatment by filling a prescription for a 
non-index product (12.4% vs. 9.2%, p = 0.002) compared to patients without a baseline 
testosterone assay. This study suggests that a baseline testosterone assay improves 
treatment benefits by increasing the likelihood of follow-up testosterone level 
monitoring, continuation of index treatment, continuation of a non-index treatment, and 
decreases the likelihood of stopping treatment with the index product.29  
The current situation of TRT in the US has reached a critical point. Utilization is 
increasing despite conflicting opinions on testosterone safety and necessity. Marketing is 
encouraging patients to seek testosterone therapy, but not all patients are appropriate for 
treatment. At the same time, barriers to testosterone use such as PA and ST may be 
limiting access to needed testosterone. Other avenues not captured in claims data may be 
used, such as cash payment or use of clinics. The patients that are appropriate may not be 
consistent in TRT use. MCOs are left to deal with increased costs related to TRT as well 
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as ensuring appropriate use of TRT. One way MCOs can manage a situation where 
safety, appropriate use, and costs of a therapy are in question is the use of PA.  
PRIOR AUTHORIZATION (PA) 
According to The Academy of Managed Care Pharmacy (AMCP), prior authorization 
(PA) is an essential tool used by MCOs to control utilization of and expenditures for 
selected medications. Usually these medications are very expensive, have serious side 
effects, or a less expensive but similarly effective option that is preferred by the MCO is 
available. Once a medication has been identified for the PA process, the MCO determines 
the requirements for coverage of the medication using evidence-based clinical need and 
therapeutic rationale. Individual PA parameters vary by plan and medication. In most 
cases, if PA criteria are not met, the payer either does not cover the medication or the 
medication may be subject to higher copay.70  
AMCP considers PA an overarching strategy with multiple subtypes and uses.70 Each 
type of PA addresses a different aspect of an MCO’s appropriate drug use criteria. PAs 
can be used to gather necessary medical information on a patient, administer ST, enforce 
quantity management guidelines, optimize generic utilization, and manage specialty 
medications. Most employers use PA, ST, quantity limits, and ‘refill too soon’ limits. The 
rates of utilization of these strategies increased from 2011 to 2012 by the following 
amounts: PA increased 10%, ST increased 9% and quantity limits increased 7%.71  
A literature review of ST in 2011 found that PA and ST processes are not distinctly 
unique throughout the literature.62 However, in 2014 a literature review of formulary 
restrictions on multiple outcomes treated ST and PA as separate formulary management 
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techniques.8 Therefore, a separate review of ST is necessary. 
Step Therapy 
As of 2012, ST was used by 74% of large employers and 56% of small employers.71 
The use of ST is common among Medicare Part D plans.62 ST requires a trial with a first-
line medication prior to receiving coverage for a second-line agent. For example, the 
first-line medication may be a generic. The second-line medication may be the preferred 
brand name drug. Another example occurs when the first-line medication is a preferred 
brand name drug and the non-preferred brand is the second-line medication. ST 
prioritizes established and cost-effective therapy use prior to progressing to other 
therapies that may not have well established safety, effectiveness, or value.62  
ST can be administered using online adjudication with automated logic to review the 
patient’s prescription profile. In the case of ST, if the patient already has an adequate trial 
of the first-line therapy, the second-line may be approved automatically. This method 
minimizes patient, physician, and pharmacist disruption and ensures that preferred 
products are dispensed.62  
Evaluation of Prior Authorization Effectiveness 
The measure of effectiveness of a PA program depends on the initial goal of the PA 
program and the perspective of the evaluation. While cost and utilization are usually the 
main focus, there are many unintended consequences of a PA program that should also be 
considered. Administrative costs and impacts, changes in patient adherence and 
outcomes, costs to physicians and costs to pharmacists may also be considered.72 A 2009 
literature review on PA programs found that quality measures are rarely, if ever, used to 
 33 
evaluate drug management programs.72 Plan- or payer-focused endpoints were most 
common (68%). Among those endpoints, evaluation of plan drug cost (62%) and plan 
drug utilization (30%) occurred most frequently. Among studies that evaluated benefit 
restrictions, 40% evaluated patient-focused outcomes such as patient satisfaction, and 
38% had clinically-focused outcomes such as a clinical marker.72 
PA programs have significant administrative consequences. PA programs cost $15-
$25 per claim processed yet administrative costs for restriction programs are not 
consistently included in the evaluation of drug management programs.72 Consequently, 
the financial impact of administering the program often goes unrecognized by the payer.    
PA is a way for MCOs to adhere to contractual obligations to pharmaceutical 
manufacturers. There are increasing numbers of agreements between payers and 
manufacturers based on market share or formulary position for medications. In order for 
payers to continue to receive preferential pricing, they must adhere to the terms of their 
contracts, which may require some type of drug preference program.73 As these contracts 
become increasingly important to payers, the use of PA to enforce drug preference 
programs and meet contractual requirements will also become more important. This 
means that it is likely that PA programs will be needed by payers unless a better system is 
developed. 
PA is most likely to reduce costs and utilization in drug classes with the following 
characteristics: generic products are available, treatment of a condition with mild to 
moderately severe symptoms, and availability of brand name drugs with limited 
advantages over generics in that class.74 In an ideal situation, PA programs should have a 
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favorable effect on cost and quality of care, but they should not cause negative health 
outcomes. However, an analysis by Carroll in 2002 found that most PA programs do not 
meet these ideal conditions and that negative health outcomes as a result of PA are 
possible.74  
Utilization management mechanisms such as PA and ST have been linked to non-
adherence. In 2004, Motheral et al. studied the effects of ST programs on patients. They 
surveyed patients who experienced ST for either proton pump inhibitors, non-steroidal 
anti-inflammatory medications, or selective serotonin receptor inhibitors within 7 months 
of the ST experience. They found that 17% of patients received no medication following 
the ST experience.75 
Another study used pharmacy claims to track patients attempting to receive aliskiren 
for hypertension.76 The need for aliskiren was assumed to indicate the current therapy 
was not meeting goals and additional therapy was needed. PA, ST, or non-formulary 
placement utilization management tools were in effect during the study. After receiving a 
rejected claim, 28.4% of the patients did not receive any type of additional 
antihypertensive, dose escalation, or combination of additional and escalation. Therefore, 
despite the assumed need for additional therapy, the therapeutic needs of those patients 
may not have been met because of the utilization management tools in place.76 
A 2014 meta-analysis of managed care formulary restrictions found that PA 
negatively impacted adherence in 68% of studies.8 The authors also found no distinct 
trends in the relationships between PA and broad economic measures such as total 
medical costs, total costs, and total pharmacy costs. Overall, the authors found a lack of 
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research assessing the impact of formulary restrictions on medication adherence among 
other outcomes.8 
In summary, PA programs offer the possibility of cost savings and utilization control, 
but those benefits may come at a cost. As of July 1, 2014, the top two pharmacy benefit 
managers in the US, ESI-Medco and CVS Caremark, have some form of PA in place for 
testosterone products.77,78 Until now, evaluations of testosterone use behaviors have not 
taken into account how pharmacy benefit design, such as the use of PAs or ST, impact 
testosterone patients despite widespread use. The implementation of PA and ST for 
testosterone in the DoD MHS offers a unique setting to evaluate how these utilization 
management tools impact TRT patients.  
THE DEPARTMENT OF DEFENSE MILITARY HEALTH SYSTEM 
The DoD is responsible for the health care for 9.5 million beneficiaries. In 2014, 
78.9% of those eligible used MHS services.79 The DoD MHS is a separate medical 
system from the VHA. Patients qualify for medical benefits in the MHS either by serving 
on active duty or through 30 days of active service in the National Guard or Reserve. 
Spouses and children of those who serve are also eligible. Following 20 years of active 
service, active duty members are eligible to retire. Medical benefits for retirees and their 
spouses continue for life. If an active duty member separates from the military (rather 
than retiring), they are not eligible for continued medical benefits unless special 
circumstances have occurred such as significant medical disability due to service. 
Patients who separate may be eligible for care through the VHA.80 Only 17% of military 
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members will retire.81 The remaining 83% separate from the military and therefore no 
longer qualify for medical benefits under the MHS.81 
The MHS has the following four overarching goals: increase readiness, keep 
people healthy through population health initiatives, provide the best experience of care 
possible, and lower per capita costs through a focus on quality and eliminating waste.82 
The mission of the MHS is unique compared to other health care payers. One of the 
major responsibilities of the MHS is maintaining the war fighter’s ability to deploy. 
Another unique quality is the proportion of patients who are retirees and their families 
over the age of 65 (23%), retirees and their families under 65 (34%) and the fact that the 
MHS is responsible for the health care of these patients for life.82 By 2020, the MHS 
projects 43% of the MHS population will be males 45 years old or older.79 
The MHS is comprised of military treatment facilities (MTF) and purchased care 
through civilian facilities. Tricare, the program that administers the DoD health care 
program, integrates MHS resources as well as purchased care from civilian health care 
providers. Beneficiaries can choose from different Tricare health plans.79 Tricare Prime 
and Tricare for Life make up 66% and 28% of the enrolled MHS population, 
respectively.79 
Individuals eligible for Tricare Prime include active duty service members and 
their families, retired service members and their families (that are not using Tricare For 
Life), activated Guard and Reservists and their families, and other miscellaneous groups 
of beneficiaries. Tricare Prime provides primary care managers, preventative health 
services, arrangement for specialty provider services, and pharmacy benefits. Tricare for 
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Life is a Medicare wraparound coverage and secondary payer for beneficiaries 65 years 
or older who have Medicare Parts A and B. The majority of beneficiaries 65 years or 
older are covered by Tricare for Life as their supplemental plan. Approximately two 
million beneficiaries are enrolled in Tricare for Life comprising 28% of all enrollees.79  
Pharmacy benefits are available at MTFs, a retail pharmacy network of 55,000 
pharmacies, and a Tricare Mail Order Pharmacy (TMOP).83 In 2012, the DoD spent $7 
billion on drug expenditures after accounting for pharmaceutical manufacturer refunds.83 
The annual budget for the entire DoD medical program for fiscal year 2015 was $58.5 
billion.79 
DoD beneficiaries, including Tricare Prime and Tricare for Life, can use four 
main pharmacy points of service. MTF, TMOP, retail network, and non-network retail 
pharmacies are available and have varying copays. At MTF patients may receive up to a 
90-day supply of medication and there is no copay. Through TMOP, patients may receive 
up to a 90-day supply of medication. This includes schedule III-V controlled substances 
as allowed by the prescriber. Network retail pharmacies include major pharmacy chains 
throughout the US. The copays for each point of service are available in Table 2.1. 
Non-network pharmacies are the most expensive for patients and will not be 
included in this study. If patients use pharmacies outside the network, the patient files a 
claim for reimbursement and is subject to deductibles, out-of-network cost-shares, and 
copays of 20% to 50% of total cost depending on the beneficiary type. This results in 
significantly higher out-of-pocket costs for the patient compared to the other three points 
 38 
of service.84 Additionally, the manual claim submitted by the patient may not be available 
in the patient’s military prescription claims database. 
On February 1, 2013 the DoD adjusted copays at all pharmacy points of service.85 
Table 2.1 summarizes the copayment structure before and after the adjustment.82,84 The 
goal of the change was to incentivize use of the MTF and TMOP options by offering $0 
copays for generic drugs at those points of service. By lowering the copayments to $0, 
financial barriers are removed for obtaining medications in those categories. This also 
means the copays for the other points of service, especially for brand or non-formulary 
medications, became very high (in comparison) which could negatively impact adherence 
rates for those medications.86 
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Table 2.1: Department of Defense Copay Structure 
 October 1, 2011–
February 1, 20131 
February 1, 2013–
February 28, 20142 
Military Treatment Facility 
Generic $0 $0 
Brand $0 $0 
Non-formulary n/a n/a 
Home Delivery/Tricare Mail Order Pharmacy (90-day supply) 
Generic $3 $0 
Brand $9 $13 
Non-formulary $25 $43 
Network Retail Pharmacy (30-day supply) 
Generic $5 $5 
Brand $12 $17 
Non-formulary $25 $44 
Note: Active duty service members have no copay at any point of service for formulary medications. Non-formulary medications 
require medical necessity approval. If approved there is no copay. 
 
1 Evaluation of the Tricare Program: Access, Cost, and Quality. 2013. Available at:   
http://www.tricare.mil/tma/dhcape/program/downloads/TRICARE2013%2002_28_13%20v2.pdf. Accessed November 25, 2013. 
2 Tricare Pharmacy Program Handbook. 2014. Available at: 
http://www.tricare.mil/~/media/Files/TRICARE/Publications/Handbooks/Pharmacy_HBK.pdf. Accessed July 9, 2014. 
 
MHS patients are subjected uniformly to the same guidelines, copays, and 
formularies on the same timeline. Claims data from military, mail order, and retail 
pharmacies are available. These data can be used retrospectively to evaluate drug benefit 
trends MHS wide. Recently these were used to evaluate overall trends and persistence of 
testosterone therapy in the DoD. 
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Testosterone in the Department of Defense Military Health System 
Trends in testosterone use that occur in civilian populations have also occurred in 
the DoD population. A 2015 study by Canup et al. found that prescriptions for androgens 
(all forms) dispensed at MTFs increased dramatically from 19,143 in 2007 to 44,860 in 
2011.87 The authors found the largest increase in use in patients 35 to 44 years old. 
Finally, the authors examined changes in coding for testicular hypofunction from the 
Defense Medical Epidemiology Database. While coding for testicular hypofunction 
increased 45.5% annually from 2007 to 2011, the increased rate of androgen use was only 
23% per year. The number of androgen prescriptions to hypofunction diagnosis decreased 
throughout the study period. One reason authors believe this ratio may have decreased is 
the possibility of treatment with testosterone without a diagnosis or initial testosterone 
level testing.87  
Another testosterone study in the DoD is a 2013 retrospective study of 
testosterone utilization and persistence behaviors from 2002 – 2012. From 2002 – 2012, 
the number of men receiving prescriptions for testosterone (topical and buccal) each year 
grew from 8,124 in 2002 to 63,014 in 2012 resulting in an increase in prevalence from 
0.35% to 1.91%.  Costs grew from $4.9M annually in 2002 to $79.5M in 2012. From 
2011 to 2012 alone, costs increased 35%.88 Figure 2.1 shows the total cost for each 
product type dispensed by year. Figure 2.2 shows the number of prescriptions dispensed 
in each age group annually from 2002 – 2012. During the 2010 to 2012 study period, 
there were no pharmacy benefit restrictions (such as PA, ST, medical necessity (MN) 
requirements, or formulary restrictions) on testosterone prescriptions.89  
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Figure 2.1: Testosterone Spending, 2002 – 2012, by Product Type 
 
Roska E, Wilson J. Testosterone Prescribing and Persistence Trends in the Department of Defense, 2002-2012: A Retrospective 
Analysis. 2014. 
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Figure 2.2: Testosterone Prescriptions, 2002 – 2012, by Age Group 
 
Roska E, Wilson J. Testosterone Prescribing and Persistence Trends in the Department of Defense, 2002-2012: A Retrospective 
Analysis. 2014. 
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Androgel 1.62% in 2011. While this study could not conclude that direct-to-consumer 
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persistence rate of 45% without a 30-day gap, 65% without a 60-day gap, and 33% 
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implemented PA and ST for testosterone products (not including implants and 
injectables) in order to encourage safe, appropriate use of testosterone while 
simultaneously controlling costs. The DoD Pharmacy and Therapeutics (P&T) 
Committee developed the guidelines for use at their August 2012 meeting.90 According to 
meeting minutes, a budget impact analysis indicated the most cost-effective situation was 
to recommend Fortesta (testosterone gel by Endo) as the first-line agent. Patients 
impacted by the formulary change were notified of the change by a letter. The letter is 
available in Appendix B. 
Ultimately three separate processes were implemented. First, PA criteria were 
established for any use of testosterone. Second, ST guidelines positioned Fortesta as the 
first-line agent. MN criteria were established for patients wishing to use any non-
preferred agent. Finally, for topical forms of testosterone, a screening process was 
established to detect potential safety issues due to product transfer to household 
contacts.90  All three forms are in Appendix C: Department of Defense Forms.   
For males, the PA criteria for testosterone use are a history of two or more 
morning testosterone levels below 300 ng/dL and hypogonadism symptoms. These 
criteria are consistent with the Endocrine Society treatment guidelines for hypogonadism. 
According to the ST guidelines, all patients, new or established on testosterone, must fail 
Fortesta before qualifying for all other non-injectable forms of testosterone. Due to 
concerns of contact transfer of topical testosterone, patients must have a low risk of 
hazardous skin transfer to family members in order to receive a topical product. Patients 
could not be “grandfathered” for testosterone treatment. In other words, all testosterone 
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patients, new and established, would have to go through the PA and ST process.90 The 
“no grandfathering” policy was atypical for a DoD PA.84 Motheral found that programs 
that do not grandfather patients through ST requirements have larger cost savings 
compared to those that grandfather.62  
All three pharmacy points of service (POS) are responsible for following DoD 
formulary guidelines.91 The process at the MTF differs from retail and TMOP. Figure 2.3 
shows the PA process for the DoD at a retail and a TMOP pharmacy POS. Figure 2.4 
shows the PA process at MTF pharmacies. The DoD pharmacy benefit at retail and 
TMOP has been administered by Express Scripts, Incorporated (ESI) since 2003. The 
contract with ESI was renewed in 2014 for an additional seven years. ESI is responsible 
for ensuring that PA and ST guidelines established by the DoD P&T are executed 
accurately at the retail and TMOP points of service.92 
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Figure 2.3: DoD Retail and Mail Order Pharmacy PA and ST Process for Testosterone
DoD Retail and Mail Order Pharmacy PA and ST Process for Testosterone
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At the MTF, the pharmacy personnel are responsible for ensuring that the PA or 
ST guidelines are enforced. In MTFs with in-house military providers, prescriptions are 
submitted to the pharmacy via physician order entry (POE) or written, faxed, or e-
prescribed prescriptions from civilian providers. The pharmacy claim is generated in the 
Pharmacy Data Transaction Service (PDTS) as soon as the prescription is processed at 
the MTF. If a patient does not meet PA or ST guidelines, the claim should be reversed 
and the prescription should not be dispensed. 
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Figure 2.4: DoD MTF Pharmacy PA and ST Process for Testosterone 
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The results of the DoD study regarding implementation of PA and ST programs 
for testosterone have not been published. The implementation of the DoD PA/ST criteria 
for testosterone provides an opportunity to add to the literature on testosterone use, PA, 
ST, and how they influence persistence, adherence, and other behaviors using a 
population and setting well suited for this type of study. The following section describes 
this proposed study in further detail. 
RATIONALE AND OBJECTIVES FOR THE STUDY 
MCOs and the DoD responded to increased testosterone utilization by putting PA 
and ST programs in place in order to ensure safe, appropriate use of testosterone and to 
contain costs. At the same time, there is evidence that patients are inconsistent in TRT 
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use but the reasons for this behavior are not clear. Previous studies have failed to account 
for the widespread use of PA and ST programs for testosterone products. These programs 
restrict access to testosterone possibly contributing to low persistence or adherence rates, 
switching, restarting, and cycling behavior. Additionally, the extent to which testosterone 
PA or ST have influenced testosterone utilization and medication costs is unknown.  
The DoD PA and ST programs are unique because all patients, even established 
testosterone users, were required to complete the PA and ST process. Therefore, this 
particular situation allows for comparison of patient behavior before and after the PA and 
ST. In addition, a “no-grandfathering” policy for PA and ST programs is atypical for the 
DoD, and review of the results of this deviation from normal operations may impact 
future policy decisions. Finally, greater understanding of switching, restarting, and 
cycling behaviors is needed. This study expands the understanding of testosterone use 
behaviors that previously may have been considered non-persistent. A retrospective 
evaluation of utilization, costs, and medication use behaviors in testosterone therapy is 
warranted and will contribute significantly to the growing literature on testosterone and 
the impacts of formulary management tools on medication use behaviors. 
The purpose of the following study is to evaluate changes in testosterone costs, 
utilization, and medication use behavior before and after implementation of DoD PA and 
ST programs on March 1, 2013 as well as measure testosterone use behaviors. The study 
objectives are listed below and the hypotheses for each objective are available in Table 
4.18. 
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1. Describe medication costs, number of new users, number of 30-day equivalent 
prescriptions, proportion of prescriptions by pharmacy POS, proportion of 
prescriptions by product, mean patient age, and mean daily dose before and after 
PA and ST program initiation in the DoD. 
2. Compare adherence and persistence before and after implementation of the PA/ST 
program. 
3. Compare adherence behaviors in testosterone users before and after PA and ST 
program initiation in the DoD while controlling for covariates (starting dose, 
overall average daily dose, age, copay, point of service, and product type). 
4. Compare persistence behaviors in testosterone users before and after PA and ST 
program initiation in the DoD while controlling for covariates (starting dose, 
overall average daily dose, age, copay, point of service, and product type). 
5. Determine switching, restarting, and cycling patterns post PA/ST, by product 
type, overall average daily dose, point of service, and age group. 
6. Compare mean gap days between the last prescription in pre-period and the first 
prescription in the post-period to average gap days overall. 
  
 49 
Chapter 3:  Methods 
This chapter describes the methods of this study. First, the study design and data 
source, including inclusion criteria and data collection, are presented. Second, 
independent and dependent variables of interest are defined. Third, the statistical analysis 
for each hypothesis is concludes this chapter.  
INSTITUTIONAL REVIEW BOARD SUBMISSION 
This study was reviewed by The University of Texas at Austin Institutional 
Review Board. This protocol was determined to be non-human subjects research due to 
the secondary use of a de-identified data set. In addition, this protocol was approved by 
The Defense Health Agency (DHA) Privacy and Civil Liberties Office and executed 
under an approved Data Sharing Agreement (DSA). 
STUDY DESIGN  
This was a retrospective, secondary database analysis of prescription claims. 
Specific inclusion and exclusion criteria are listed under inclusion and exclusion criteria. 
In general, the claims in this study include adult men, 18 years of age or older, from the 
Department of Defense (DoD) Military Health System (MHS) who received testosterone 
(other than injectable or implant) anytime from March 1, 2012 through February 28, 
2014. The intervention date for the study is March 1, 2013, the day the DoD prior 
authorization (PA) and step therapy (ST) programs were implemented. Figure 3.1 
presents a timeline of the study. 
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Figure 3.1: Study Timeline 
 
 The look-back period, March 1, 2011 through February 28, 2012, was used to 
determine if patients received a testosterone prescription in the year preceding the 
beginning of the study on March 1, 2012. In order to be included in the overall group of 
patients, patients must have had at least one prescription in the time period from March 1, 
2012 to February 28, 2014. The paired group of subjects, a subset of the overall group of 
study subjects, was used for pre-PA and post-PA inferential comparisons. In order to be 
included in the paired group, patients must have had at least one prescription during the 
pre-PA period from March 1, 2012 to February 28, 2013 and at least one prescription 
during the post-PA period from March 1, 2013 to February 28, 2014. The index study 
prescription was the first prescription claim for each patient occurring on or after March 
1, 2012.  
Inclusion Criteria 
The following inclusion criteria were used: men enrolled in Tricare For Life or 
Tricare Prime; 18 years old or greater, and received a prescription for Androgel, Testim, 
Axiron, Androderm, Testoderm, Fortesta, Striant, Vogelxo, or a generic topical 
testosterone product during the time period March 1, 2012 through February 28, 2014. 
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The paired group will then be limited to those patients with one prescription in the pre-
PA period and one prescription in the post-PA period. Appendix A: Included 
Testosterone Forms provides a summary of products included in this study. A nasal gel 
was approved in May 2014, but at the time of study design was not commercially 
available and therefore not included.93 Paid prescription claims were included in the 
analyses.  
Exclusion Criteria 
Patients using injectable and implantable forms of testosterone were not included. 
These claims are not consistently processed as pharmacy claims. Rather, those claims 
often result from office-based procedures. Patients under the age of 18 years old were not 
included because these patients would not qualify through the PA/ST process in this 
study and would instead require a separate process not of interest for this study. Claims 
made to the Veteran’s Health Administration (VHA) and in theater (deployed) were 
excluded.  
Data Source 
The data source for this study is the DoD Pharmacy Data Transaction Service 
(PDTS). The DoD PDTS contains prescription claim data for all DoD beneficiaries.94 
Each record in the PDTS represents an outpatient prescription claim filled for an MHS 
beneficiary.94 The PDTS contains information on the claim, pharmacy, provider, patient, 
and drug dispensed. The claim section contains information such as whether the claim 
was for a compounded medication, date dispensed, day supply, whether the claim was for 
a generic product, reject codes, quantity dispensed, type of pharmacy, costs, and copays. 
 52 
The provider section contains the address and identification number for the prescriber. 
The patient section contains information such as age, identification number, patient or 
sponsor branch of service and beneficiary status (retired, active, reserve, family member). 
The drug section contains brand name, generic name, American Hospital Formulary 
Service (AHFS) classification, dosage form, generic code number (GCN), generic name, 
route of administration, and strength.95 Only the fields required to conduct this study 
were requested. PDTS data are not publicly available, but data can be requested through 
the DHA Civil Liberties Office with a government sponsor.94  
Data Collection 
Fields for data collection were selected from the MHS Mart which lists the field 
available for multiple systems including PDTS.95 Specific fields were selected based on 
the most current listing available at the time of data extraction. Data were de-identified 
by replacing patient-specific identification numbers with randomly generated patient 
identifiers. This process was conducted by the staff at the DoD Pharmacoeconomics 
Center, now known as the Pharmacy Operations Division. 
STUDY VARIABLES 
The following section defines and explains the dependent and independent 
variables used in the study. 
Dependent Variables 
Total medication cost is the sum of the total amount paid by the DoD overall for 
each prescription included in the observation period. This was reported descriptively. 
 53 
Rebates and refunds are not included in calculations and were not available for this study. 
Cost totals were not adjusted for copays. 
Patients with “new user status” are incident users. This includes any patient 
receiving a testosterone prescription who did not receive any other included form of 
testosterone in the previous year. Claim data from March 1, 2011 through February 29, 
2012 were used only for look-back purposes. New user status can occur during the pre-
PA or post-PA time period. This variable was designed to establish if there are fewer 
incident users after the PA and ST are implemented. 
The MHS allows prescriptions for up to a 90-day supply; therefore, prescription 
volume should be standardized to 30-day equivalents for comparisons. The days supply 
for each claim divided by 30 (days) establishes the 30-day equivalent for each 
prescription. For example, if a 90-day supply prescription is dispensed, it is worth three, 
30-day equivalents (90-day supply divided by 30 equals three). This allows for 
standardized comparisons across prescriptions of varying day-supplies. 
The proportion of prescriptions by pharmacy point of service (POS) is a 
description of the percentage of the total number of prescriptions filled at each pharmacy 
POS. The same applies to the proportion of prescriptions by product but that is the 
percentage of prescriptions filled for each product. Calculations for the mean daily dose 
are discussed under the Independent Variables section. 
Adherence was measured using the medication possession ratio (MPR). It was 
calculated as the total days supply for the prescriptions during the observation period 
divided by the refill interval. The refill interval was calculated by adding the days’ supply 
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of the last prescription to the difference between the last prescription date and the first 
prescription date. MPR calculations for the pre-PA period and post-PA period were 
calculated using the date range for the pre-PA period and the post-PA period. 
The range of MPR was not allowed to exceed “1.00”. A dichotomous measure of 
adherence was determined by the MPR value. Any patient with an MPR of 0.8 or greater 
was considered adherent. Any MPR less than 0.8 was considered non-adherent.  
MPR was used in this study because patients were not expected to use more than 
one type of testosterone at any given time. However, if a patient is on more than one type 
of testosterone simultaneously, both types of testosterone were considered concurrently, 
and the MPR was capped at “1.00” to account for possible double counting of therapy 
days.  
Persistence was the length of therapy in days (days supplied) from either March 1, 
2012 through February 28, 2013 (pre-PA/ST) or March 1, 2013 through February 28, 
2014 (post-PA/ST) before an unacceptable gap in therapy or the end of the study period. 
The first prescription during the March 1, 2012 through February 28, 2013 time period 
was the index date for the pre-period. The post-period began with their first prescription 
following the PA/ST implementation on March 1, 2013.  
Persistence days, or length of therapy, was a continuous measure of persistence 
defined as the number of days the patient persisted on therapy before an unacceptable gap 
or the end of the study period. Unacceptable gaps of 30 days, 60 days, and 1.5 times the 
previous day’s supply were used for sensitivity analysis. In the event the patient does not 
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have an unacceptable gap in therapy, the number of days from start of therapy until the 
end of the observation period was used.  
Switching occurred when a patient filled a prescription for any form of 
testosterone other than the previous product at any time before the end of the study on 
February 28, 2014. Patients who switched can be adherent or non-adherent, persistent or 
non-persistent, cyclical or restarting patients. The switch status, a dichotomous variable 
(switched or did not switch), was established for each paired patient. Product switching in 
the post-PA period was reported. 
Restarting and cycling behaviors occur in patients who are considered non-
persistent. Figure 3.2 shows how there are multiple paths for these patients and how 
persistence, switching, restarting, and cycling occur.  
Figure 3.2: Patient Behavior Pathway /   
Prescription for 
testosterone
Persistent
Switched
Did not switch
Non-persistent
Restarted
Cycled
Switched
Did not switch
Did not cycle
Switched
Did not switch
Discontinued
Discontinued
 
Restarting is considered refilling any testosterone product after a gap in therapy of 
more than 30 days. Schoenfeld et al. considered patients “restarting” if they went back to 
their index form of testosterone after a break in therapy of 30 days5; however, it is 
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possible for patients to restart on a different agent, especially after a PA or ST. In this 
study a restart included restarting any testosterone therapy after a 30-day gap in therapy. 
The restart status is a dichotomous variable indicating the patient restarted or did not 
restart. 
Cycling occurs when a “restarted” patient has a break in therapy of 30 days or 
more and then restarts therapy again. These patients “cycle” because they are not 
continuously adherent or persistent, but have not stopped therapy all together. Patients 
may repeat this cycle of a gap in therapy of more than 30 days and then filling a 
prescription multiple times. Figure 3.3 compares each of these behaviors. Each row 
represents a different behavior and the colored areas represent a time period that the 
patient has medication. Each group of four columns represents a month of therapy.  
Figure 3.3: Potential Behavior Patterns
 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 
Adherent                         
Persistent                         
Switching                         
Restarting                         
Cycling                         
 
 “Gap days” are the number of days from the expected end of a prescription (the 
date dispensed plus the days supply) to the next successful prescription claim date. In this 
study, the gap days from the expected end of the last prescription in the pre-PA period to 
the first prescription in the post-PA period were investigated specifically and called the 
‘PA gap days’. 
 57 
Independent Variables 
 The PA/ST status indicates if the prescription occurred before or after the PA/ST 
implementation. The pre-period is March 1, 2012 to February 28, 2013. The post-period 
is March 1, 2013 to February 28, 2014.  
Variables related to dose must be calculated. First, the quantity of the product 
dispensed in each claim is multiplied by the strength of the product dispensed in order to 
determine the total amount in milligrams of testosterone dispensed in that particular 
prescription. The total amount of testosterone dispensed is then divided by the number of 
days supplied in that prescription. This results in the average dose (in milligrams) per day 
for that prescription. In order to standardize doses across various forms of testosterone, 
the dose per day will be converted into a proportion of the recommended starting dose 
(PRSD) for each product. Recommended starting doses for each product are available in 
Appendix A. For example, one bottle of Androgel 1.62% metered dose pump contains 
1,215 mg of testosterone. The recommended starting dose is 40.5 mg daily. Therefore, in 
this case, at the recommended starting dose, one bottle of Androgel 1.62% metered dose 
pump is a 30-day supply of medication. This prescription is 1.00 of the PRSD. If the 
patient increases to two bottles every 30 days, the dose per day changes to 81 mg per day. 
Therefore, the new PRSD is 2.00. The starting or initiating dose is the PRSD for the 
index prescription for each patient. Overall average daily dose is the average PRSD for 
all of the prescriptions for each patient. 
Age, copay amount, and POS are all reported in each prescription claim. Age is 
the age at index. POS is the type of pharmacy used: retail, mail order, or MTF at index. 
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Product type is a categorical list of each product included in the study. Product brand is a 
categorical list of each product brand included in the study. Appendix A is a list of the 
included products.  
STATISTICAL ANALYSIS 
Statistical analysis was performed using PASW Statistics for Windows, Version 
18.0 (SPSS Inc., Chicago) and IBM SPSS Statistics for Windows, Version 23.0 (Amonk, 
NY: IBM Corporation).96,97 All inferential statistics used two-tailed tests and a 
significance cut-off of 0.01. Paired t-tests, multivariate regressions, and logistic 
regressions were used to test hypotheses. All power analyses were conducted using 
G*Power 3.1.9.2 for Windows.98,99 
Paired T-test 
A paired t-test is used to test for a difference of means between paired 
observations that differ on the independent variable. The assumptions for a paired t-test 
are normality and homogeneity of variance.  
Several studies inform an estimate of effect size for each t-test. The PA/ST 
program in this study did not allow grandfathering. A meta-analysis of ST programs 
indicated that programs that do not grandfather have the largest savings.62 Delate et al. 
and Smalley et al. found 50% (SD not given) and 53% (SD = 17.96) reductions 
respectively in drug expenditures after implementing ST programs with no 
grandfathering.100,101 This suggests the effect size for reduction in expenditures could be 
as high as 0.65. For PA/ST programs that do grandfather, the effect size is likely much 
lower.62 Therefore, effect sizes ranging from 0.1 to 0.65 were used for power analysis. 
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Due to the potential for a large population in this study, power was set at 95% and the 
lower limit of effect size was assumed to be as conservative as possible (0.1). Therefore, 
an estimated total n of 1,785 was needed. 
Multiple Regression 
Multiple regression is used to predict a dependent variable from a set of 
predictors. Objectives three and four use multiple regression to predict MPR in the post-
PA period or persistence days in the post-PA period using the pre-PA MPR or persistence 
days, respectively, while controlling for covariates. Each objective has one predictor 
variable of interest.The following assumptions must be met: 1) there is a linear 
relationship between the dependent and independent variables; 2) lack of 
multicollinearity (or correlation between independent variables); 3) independence of 
observations; 4) homoscedasticity of variance; and 5) normal distribution of residuals. 
The regression model is as follows: 
Y = β0 + β1X1 + β2X2 + β3X3 + … + βnXn 
Y = dependent variable 
β0 = Intercept 
β1 to βn = regression coefficients 
X1 to Xn = independent variables 
 
Due to the potential for a large population in this study, power was set at 0.95 and 
the lower limit of effect size was assumed to be as conservative as possible (0.1). 
Therefore, an estimated total n of 292 was needed.  
Logistic Regression 
Logistic regression uses independent variables to predict a dichotomous 
dependent variable. Observations must be independent in order to meet logistic 
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regression assumptions. Objective five uses several independent variables to predict 
switching, restarting, and cycling patterns. The regression model is as follows: 
Logit [ θ (x) ] = log [ θ (x) / 1 - θ (x) ] = β0 + β1X1 + β2X2 + β3X3 + … + βnXn 
θ (x) = probability of success 
1 - θ (x) = probability of failure 
β0 = constant of equation 
β1 to βn = regression coefficients 
X1 to Xn = independent variables 
For the power analysis, odds ratios for switching, restarting, and cycling patterns 
were estimated from existing literature. According to Schoenfeld et al., the probability of 
switching was 5%. This yields an odds ratio of switching to not switching of 0.0027. The 
odds of not switching are 361 times higher than switching. Restarting, however, occurred 
in 33% of patients which results in an odds ratio of 0.25. The odds of not restarting were 
four times higher than restarting.5 According to Donatucci et al., 59% of patients had at 
least one episode of cycling.7 This corresponds to an odds ratio of 2.07. The odds of 
cycling are twice the odds of not cycling. These literature-based odds ratios were used to 
calculate the required sample size. In addition, R-squared was varied from 0.1 to 0.3.  
These sample size calculations are summarized in Tables 3.1 – 3.3. For switching, 
at least 9,406 subjects are needed. For restarting, at least 6,771 subjects are needed. For 
cycling, at least 4,584 subjects are needed. The highest sample size needed is 9,406. 
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Table 3.1: Logistic Regression Power Calculations – Switching 
Odds ratio 0.0027 0.01 0.05 0.1 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.1 0.1 0.1 0.1 
n required 7316 3437 1812 1623 
     
Odds ratio 0.0027 0.01 0.05 0.1 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.2 0.2 0.2 0.2 
n required 8230 3866 2039 1825 
     
Odds ratio 0.0027 0.01 0.05 0.1 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.3 0.3 0.3 0.3 
n required 9406 4418 2330 2086 
Y = dependent variable; X = independent variables; α = 0.01 (two-tailed); β = 0.05(power 
= 95%); assumes a Poisson distribution for the independent variable of interest 
a Probability of an event under H0. The modeled event was switching. 
b When independent variable of interest is regressed on the other independent variables or 
covariates in the regression 
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Table 3.2: Logistic Regression Power Calculations – Restarting 
Odds ratio 0.25 0.4 0.5 0.6 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.1 0.1 0.1 0.1 
n required 1874 2628 3565 5266 
     
Odds ratio 0.25 0.4 0.5 0.6 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.2 0.2 0.2 0.2 
n required 2109 2957 4011 5924 
     
Odds ratio 0.25 0.4 0.5 0.6 
Pr(Y=1│X=1)H0
a 0.03 0.03 0.03 0.03 
R-squaredb 0.3 0.3 0.3 0.3 
n required 2410 3379 4584 6771 
Y = dependent variable; X = independent variables; α = 0.01 (two-tailed); β = 0.05(power 
= 95%); assumes a Poisson distribution for the independent variable of interest 
a Probability of an event under H0. The modeled event was restarting. 
b When independent variable of interest is regressed on the other independent variables or 
covariates in the regression 
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Table 3.3: Logistic Regression Power Calculations – Cycling 
Odds ratio 0.5 1.5 2.0 2.5 
Pr(Y=1│X=1)
H0a 
0.03 0.03 0.03 0.03 
R-squaredb 0.1 0.1 0.1 0.1 
n required 3565 2203 526 255 
     
Odds ratio 0.5 1.5 2.0 2.5 
Pr(Y=1│X=1)
H0a 
0.03 0.03 0.03 0.03 
R-squaredb 0.2 0.2 0.2 0.2 
n required 4011 2479 592 287 
     
Odds ratio 0.5 1.5 2.0 2.5 
Pr(Y=1│X=1)
H0a 
0.03 0.03 0.03 0.03 
R-squaredb 0.3 0.3 0.3 0.3 
n required 4584 2833 676 327 
Y = dependent variable; X = independent variables; α = 0.01 (two-tailed); β = 
0.05(power = 95%); assumes a Poisson distribution for the independent variable of 
interest 
a Probability of an event under H0. The modeled event was cycling. 
b When independent variable of interest is regressed on the other independent variables or 
covariates in the regression 
SUMMARY 
This study aims to fill a gap in knowledge that impacts the health of millions of 
men. As utilization management measures become more widely used, it is important to 
investigate all the outcomes of these actions. It is clear that the outcomes of utilization 
management not traditionally evaluated may be, in fact, just as important as medication 
costs and utilization. Simultaneously evaluating utilization management measures with 
medication use behaviors will ultimately shape the way policy is designed and evaluated 
in order to ensure the best patient outcomes.  
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Chapter 4:  Results 
OVERVIEW 
This chapter presents the results of this study. First, there is a description of the 
data extraction. The next section contains descriptive information about the study 
subjects. The final section presents the results of each objective.  
DATA EXTRACTION 
From March 1, 2012 to February 28, 2014, 78,623 patients were identified as 
having at least one prescription for Androgel, Testoderm, Fortesta, Axiron, Androderm, 
Fortesta, Striant, Vogelxo, or a generic topical testosterone product. There were 423,336 
prescriptions that met the inclusion criteria. This group represents the overall cohort of 
subjects with at least one qualifying prescription.  
The date of the implementation of the prior authorization (PA) and step therapy 
(ST) was March 1, 2013. Of the 78,623 patients identified, 26,464 (33.6%) patients only 
had prescriptions prior to the PA implementation and 18,111 (23.0%) only had 
prescriptions after the PA implementation. Patients with only one qualifying prescription 
from March 1, 2012 to February 28, 2014 made up 21.2% (16,646) of the overall cohort. 
Additionally, 11 patients had prescription claims for Testoderm, a product which was not 
available during the study period and therefore, those prescriptions were excluded as they 
may have been inappropriately labeled claims. Table 4.1 lists the results of the 
application of the exclusion criteria and Figure 4.1 depicts the patient groups. 
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Table 4.1 Patient and Prescription Exclusion 
 
Patients 
Remaining 
N (%)  
Prescriptions 
Remaining 
N (%)  
Patients with any qualifying prescription from 
March 1, 2012 to February 28, 2014 78,634 (100%)  423,486 (100%)  
Remove Testoderm prescriptions 78,623 (99.9%)  423,336 (99.9%)  
Remove patients with only one prescription 61,977 (78.8%)  406,695 (96.0%)  
Remove patients without both pre-PA and post-PA 
prescriptions 34,048 (43.3%)  302,534(71.4%)  
 
As seen in Figure 4.1, of the 78,623 overall patients identified, 34,048 had at least 
one prescription before March 1, 2013 and at least one prescription on or after March 1, 
2013. These subjects represent the paired group with at least one pre-PA and one post-PA 
prescription. Of the 60,512 patients with claims before the implementation of the PA, 
56.3% met the PA criteria and had a successful claim for an included product after PA 
implementation. Those 60,512 patients represent 77.0% of the overall 78,623 study 
subjects. Overall, 52,159 (66%) of the 78,623 patients successfully had claims after PA 
implementation. 
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Figure 4.1 Number of Patients by Category 
 
Quantity, cost, and days supply claim fields contained outlying values. An 
algorithm comparing quantity, cost, and days supply of reasonable and frequently 
occurring claims to those outliers generated adjusted values that were used in data 
analysis. For example, there were 12,946 (3.1%) claims with a quantity of one. A new 
variable was created to adjust the quantity of these claims to the appropriate package size 
corresponding to the product in the claim. A claim with a quantity of “one” for Fortesta 
was adjusted to a quantity of 60 grams for analysis. Overall, 21,779 quantity adjustments 
Pre-PA
26,464
Post-PA
18,111
Pre-PA and 
Post -PA
34,048
(Paired)
Any Pre-
PA
60,512
Any 
Post-PA
52,159
Overall 
78,623
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were made. Of those adjustments, 99.1% occurred in claims from a military treatment 
facility (MTF). 
DESCRIPTIVE RESULTS 
Demographics 
Overall Group 
The overall group (at least one prescription pre-PA or post-PA) consisted of 
78,623 patients. Retirees made up 82.6% of this group followed by active duty service 
members (11.9%). Active duty family members, guard and reserve members and their 
families, retired family members, and unknown categories make up the remaining 5.5% 
of patients. 
The mean age at index in the overall group was 59.1 (SD 12.9) years. Half of 
these patients (50.0%) were 45 to 64 years old at index. The next largest age group was 
patients age 65 and over accounting for 36.7% of the overall subjects. Patients aged 18 to 
34 years made up 3.9% of the subjects and those 35 to 44 years old made up 9.4% of the 
subjects. 
Paired Groups 
In the 34,048 paired subset (at least one prescription pre-PA and post-PA), 
retirees made up 86.1% of this group followed by active duty service members (9.4%). 
Active duty family members, guard and reserve members and their families, and 
unknown categories made up the remaining 4.5% of patients. 
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The mean age at index in the paired subset group was 60.2 (SD 12.0) years. Just 
over half of these patients (51.8%) were 45 to 64 years old at index. The next largest age 
group was patients age 65 and over, accounting for 38.6% of the subjects. Patients age 18 
to 34 made up 2.1% of the subjects and those 35 to 44 years old made up 7.4% of the 
subjects. Table 4.2 summarizes the demographics of the overall and paired groups. 
Table 4.2 Descriptive Comparison of Overall and Paired Groups Demographics 
 Overall Group 
(N=78,623) 
Paired Group 
(N = 34,048) 
Beneficiary category   
Retirees 82.6%  86.1%  
Active duty service 
members 11.9%  9.4%  
Other 5.5%  4.5%  
Mean age at index 59.1 (SD 12.9)  60.2 (SD 12.0)  
 
Clinical Characteristics 
Overall Group 
 
This section discusses the clinical characteristics of the 78,623 patients in the 
overall group. From March 1, 2012 to February 28, 2014, 53.6% of patients had an index 
prescription for an Androgel product. Specifically, 23.3% of index prescriptions were for 
Androgel 1.62% metered dose pump. Fortesta represented 19.1% of index prescriptions. 
Testim represented 11.4%, Androderm represented 8.0%, Axiron represented 7.8%, and 
Striant represented 0.2% of index prescriptions. A comparison of index products before 
and after the PA is discussed under ‘Objective One’ results.  
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The number of prescriptions per patient ranged from one to 39 with a mean of 
5.38 (4.77) prescriptions. There were 16,646 patients with one prescription, 11,604 
patients with two prescriptions, 8,555 patients with three prescriptions, 7,132 patients 
with four prescriptions, and 5,737 patients with five prescriptions. Patients with five or 
fewer prescriptions made up 63.2% of the subjects. All of the patients with 24 or more 
prescriptions had prescriptions in the pre-PA and post-PA periods.  
The mean number of products used per patient was 1.483 (SD = 0.664). Most 
patients (60.3%) used only one product. Of the 25,135 (32.0%) of patients that used two 
products, the most common combination (88.0%) was Androgel 1.62% metered dose 
pump and Fortesta. 
Most patients (82.9%) in the overall group used only one pharmacy point of 
service (POS). The most common POS by prescription claim volume was retail which 
accounted for 242,795 (57.4%) of claims followed by military treatment facilities (MTF) 
(28.7%), and mail order (14.0%). Retail claims accounted for 70.2% ($90,401,927) of 
total costs and 48.1% of 30-day equivalents dispensed.  
Each testosterone product delivers testosterone in a unique way. In order to 
compare doses of testosterone between products, a proportion of the recommended 
starting dose (PRSD) for each product was calculated for each prescription. The index 
PRSD for each patient and mean PRSD for each patient was calculated. The mean PRSD 
for the index prescriptions was 0.9993 (0.5294). The mean overall PRSD for all 
prescriptions was 1.0091 (0.4377). The recommended starting dose for each product is 
listed in Appendix A. Table 4.3 summarizes the descriptive clinical characteristics of the 
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overall group. Tables 4.4 and 4.5 present select characteristics of the 52,159 patients with 
a successful prescription following PA implementation.  
Table 4.3 Clinical Characteristics of the Overall Group 
 Overall Group (N = 78,623) 
Index product Androgel (53.6%) 
Mean prescriptions per patient 5.38 (SD 4.77) 
Number of patients with one prescription 16,646 
Number of products per patient 1.483 (0.664) 
Proportion of prescription claim volume by 
point of service  
Retail 57.4% 
Military treatment facilities 28.7% 
Mail order 14.0% 
Mean index proportion of the recommended 
starting dose 0.993 (SD 0.529) 
Mean proportion of the recommended starting 
dose 1.009 (SD 0.438) 
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Table 4.4 Frequency and Percentage of Product Brand, Point of Service, and Beneficiary 
Category in Successful Prior Authorization Patients 
 N % 
Brand of Product 
(Index) 
ANDRODERM 3,922 7.5% 
ANDROGEL 25,484  48.9% 
AXIRON 3,208 6.2% 
FORTESTA 14,025 26.9% 
STRIANT 69 0.1% 
TESTIM 5,451 10.5% 
Total 52,159 100.0% 
Point of Service Mail Order 7,061 13.5% 
Military Treatment 
Facility 15,814 
30.3% 
Retail 29,284 56.1% 
Total 52,159 100.0% 
Beneficiary Group Active duty family 462 0.9% 
Active duty service 
member 6,298 
12.1% 
Non-active duty 
family 77 
0.1% 
Non-active service 
member 1,063 
2.0% 
Retiree 43,219 82.9% 
Retiree family 1,014 1.9% 
Unknown 26 0.0% 
Total 52,159 100.0% 
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Table 4.5 Mean Age and Mean Dose of Patients with Successful Prior Authorization 
Prescriptions 
 Prior Authorization Success 
N = 52,159 
 
Mean 
Standard 
Deviation 
Age at index 
59 13 
Index recommended 
starting dose 0.99 0.51 
 
OBJECTIVE RESULTS 
This section contains the results of the hypotheses tested by each objective. Table 
4.18 summarizes the study objectives, hypotheses, and results and can be found at the end 
of this chapter. 
Objective One 
The first objective is to describe medication costs, number of new users, number 
of 30-day equivalent prescriptions, proportion of prescriptions by pharmacy POS, 
proportion of prescriptions by product, mean patient age, and mean daily dose before and 
after PA and ST program initiation in the Department of Defense (DoD). The results are 
presented in Tables 4.6 through 4.11. 
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Table 4.6 Summary Comparison of Pre- and Post-Prior Authorization Costs and 
Utilization  
 Pre-Prior 
Authorization 
Post-Prior 
Authorization Change 
Total Medication 
Costs  $ 78,186,289   $ 50,672,238  $-27,514,051 
Number of New 
Users 26,757 18,111 -8,646 
Number of 30-Day 
Equivalent 
Prescriptions 
311,391  287,063  -24,328 
Number of 
Prescriptions 222,288 201,048 -21,240 
 
The following results are reported in terms of overall prescription volume rather 
than by patient. Prior to the PA implementation, the majority of prescriptions (65.0%) pe-
PA were filled at retail pharmacies. After the PA implementation, the plurality of 
prescriptions (48.9%) were filled at retail pharmacies, however, the proportion of 
prescriptions filled at retail pharmacies decreased pre to post. MTF pharmacy utilization 
increased from 22.1% of pre-prescriptions to 35.9% of prescriptions after PA 
implementation. Mail order increased as well from 12.9% to 15.2%. As a proportion of 
all 423,336 prescriptions, these trends remain. Retail pharmacy decreased from 34.1% to 
23.2%. MTF pharmacy increased from 11.6% to 17.1%. Mail order pharmacy increased 
from 6.8% to 7.2%. Table 4.7 summarizes prescription volume by prescription POS and 
Table 4.8 summarizes total prescription volume by POS.  
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Table 4.7 Number and Percentage of Prescription Volume before and After Prior 
Authorization by Point of Service 
 
Pre-Prior Authorization Post-Prior Authorization Total 
  
Number of 
Prescriptions %  
Number of 
Prescriptions %  
Number of 
Prescriptions 
% All 
Prescriptions 
Mail 
Order 28,603  12.9% 30,477  15.2% 59,080  14.0% 
Military 
Treatment 
Facility 49,189  22.1% 72,272  35.9% 121,461  28.7% 
Retail 144,496  65.0% 98,299  48.9% 242,795  57.4% 
Total 222,288  100.0% 201,048  100.0% 423,336  100.0% 
Table 4.8 Number and Percentage of Total Prescription Volume before and After Prior 
Authorization by Point of Service 
 
Pre-PA Post-PA Total 
  
Number of 
Prescriptions %  
Number of 
Prescriptions %  
Number of 
Prescriptions 
% All 
Prescriptions 
Mail Order 28,603 6.76% 30,477 7.20% 59,080 13.96% 
Military 
Treatment 
Facility 49,189 11.62% 72,272 17.07% 121,461 28.69% 
Retail 144,496 34.13% 98,299 23.22% 242,795 57.35% 
Total 222,288 52.51% 201,048 47.49% 423,336 100.00% 
 
The market share for each product by prescription volume changed after PA 
implementation. The proportion of each product dispensed changed from pre-PA to post-
PA. The largest change was the proportion of Fortesta prescriptions. Pre-PA prescriptions 
for Fortesta represented 2.31% of the total 423,336 prescriptions. After PA, Fortesta 
represented 30.82% of the total 423,336 prescriptions. All Androgel products combined 
represented the largest proportion of prescriptions (35.1%) prior to the PA. After the PA, 
however, Androgel products represented 8.9% of total prescription volume and Fortesta 
had the largest proportion (30.8%). After PA implementation, the utilization of all agents 
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other than Fortesta decreased compared to prior to the PA. Table 4.9 summarizes the 
proportion of specific products dispensed before and after PA implementation. Table 4.10 
summarizes the brand of products dispensed before and after PA implementation. 
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Table 4.9 Number and Percentage of Prescription Volume Before and After Prior 
Authorization by Product and Strength 
 
Pre-Prior Authorization Post-Prior Authorization Total 
  
# 
Prescriptions 
% All 
Prescriptions 
# 
Prescriptions 
% All 
Prescriptions 
# 
Prescriptions 
% All 
Prescriptions 
ANDRODERM  
2 MG/24 HR  
PATCH TD24 
3,152 0.74% 2,847 0.67% 5,999 1.42% 
ANDRODERM 
2.5MG/24 HR 
PATCH TD24 
11,906 2.81% 9,471 2.24% 21,377 5.05% 
ANDRODERM  
5 MG/24 HR  
PATCH TD24 
366 0.09% 16 0.00% 382 0.09% 
ANDROGEL  
1.25G (1%)  GEL 
MD PMP 
33,219 7.85% 5,382 1.27% 38,601 9.12% 
ANDROGEL  
1.25G-1.62  GEL 
PACKET 
23 0.01% 222 0.05% 245 0.06% 
ANDROGEL  
2.5G-1.62   GEL 
PACKET 
26 0.01% 390 0.09% 416 0.10% 
ANDROGEL  
20.25/1.25  GEL 
MD PMP 
66,154 15.63% 21,845 5.16% 87,999 20.79% 
ANDROGEL  
25MG(1%)    GEL 
PACKET 
7,064 1.67% 1,445 0.34% 8,509 2.01% 
ANDROGEL   
50 MG (1%)  GEL 
PACKET 
42,392 10.01% 8,396 1.98% 50,788 12.00% 
AXIRON    
30MG/1.5ML  
SOL MD PMP 
17,871 4.22% 6,522 1.54% 24,393 5.76% 
FORTESTA   
10 MG (2%)  GEL 
MD PMP 
9,786 2.31% 130,479 30.82% 140,265 33.13% 
STRIANT  30 MG 
MUC ER 334 0.08% 275 0.06% 609 0.14% 
TESTIM 50 MG 
(1%)  GEL 
(GRAM) 
29,995 7.09% 13,758 3.25% 43,753 10.34% 
Total 222,288 52.51% 201,048 47.49% 423,336 100.00% 
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Table 4.10 Number and Percentage of Prescription Volume Before and After Prior 
Authorization by Product 
  
Pre-Prior 
Authorization 
Post-Prior 
Authorization Total 
  # Rxs1 
% Total 
Rxs1 # Rxs1 
% Total 
Rxs1 # Rxs1 
% Total 
Rxs1 
ANDRODERM 15,424 3.64% 12,334 2.91% 27,758 6.56% 
ANDROGEL 148,878 35.17% 37,680 8.90% 186,558 44.07% 
AXIRON 17,871 4.22% 6,522 1.54% 24,393 5.76% 
FORTESTA 9,786 2.31% 130,479 30.82% 140,265 33.13% 
STRIANT 334 0.08% 275 0.06% 609 0.14% 
TESTIM 29,995 7.09% 13,758 3.25% 43,753 10.34% 
 Total 222,288 52.51% 201,048 47.49% 423,336 100.00% 
1 Rxs = Prescriptions 
 
The following results are reported in terms of the 78,623 overall qualifying 
patients, rather than by prescriptions. Table 4.11 summarizes key characteristics 
comparing the pre-PA patients and post-PA pateints. The mean index age for patients 
with their index prescription occurring in the pre-PA period was 60 years (SD = 13, N = 
60,512). The mean age in patients with their index prescription occurring in the post-PA 
period was 56 years (SD = 13, N = 18,111). 
The mean PRSD in the pre-PA index patients was 1.03 (SD = 0.43, N = 60,512). 
In the post-PA period the mean PRSD was 0.92 (SD = 0.44, N = 18,111). The index 
PRSD in the pre-PA index patients was 1.03 (SD = 0.53, N = 60,512). In the post-PA 
period the index PRSD was 0.91 (SD = 0.53, N = 18,111). 
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Table 4.11 Patient Level Comparison Before and After Prior Authorization 
 Pre-Prior Authorization Post-Prior Authorization 
Number of Patients 60,512 18,111 
Mean Index Age 
(SD) 60 (13) 56 (13) 
Mean Daily 
Proportion of 
Recommended 
Starting Dose (SD) 1.03 (0.43) 0.92 (0.44) 
Mean Index 
Proportion of 
Recommended 
Starting Dose (SD) 1.03 (0.53) 0.91 (0.53) 
Most Common Index 
Product 
Androgel 1.62%  metered dose 
pump (27.3%) Fortesta (69.6%) 
Most Common Index 
Brand Androgel (65.2%) Fortesta (69.6%) 
Objective Two 
Objective two compares adherence and persistence before and after the 
implementation of the PA and ST criteria. The patients in this objective are the 34,048 
patients with at least one prescription in the pre-PA period and at least one prescription in 
the post-PA period. These patients are the paired patient group. 
The first hypothesis (Ho2a) is that there is no significant difference in adherence 
before and after PA/ST implementation. Adherence was measured using MPR. In the 
34,048 paired patients, 4,715 patients did not have two prescriptions in the pre-PA 
period. In the post-PA period, 5,160 did not have two prescriptions. Therefore, 1,435 
patients did not have two pre-PA prescriptions or two post-PA prescriptions and both pre-
PA and post-PA MPR could not be calculated. A total of 8,442 patients did not meet 
MPR criteria (at least two prescriptions) in the pre-PA and post-PA time periods. 
Therefore, the t-test included 25,606 of the 34,048 patients.  
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In the pre-PA period, 55.22% of patients achieved an MPR of 0.80 or greater. In 
the post-PA period, 53.46% of patient achieved an MPR of 0.80 or greater. A paired t-test 
showed that the mean MPR before the PA (0.7865, SD = 0.195) was slightly (but 
statistically significantly) higher than the mean MPR after the PA (0.7784, SD = 0.200) (t 
= 5.798; df = 25,605; p < 0.01). Therefore, the hypothesis is rejected.  Table 4.12 
summarizes the results of this test. 
Table 4.12 Adherence Before and After Prior Authorization (N= 25,606) 
N = 25,606 Pre- Prior Authorization Post-Prior Authorization 
MPR 
Mean (SD) 0.7865 (0.195) 0.7784 (0.200) 
 MPR ≥ 0.80  
N (%) 14,140 (55.22%) 13,689 (53.46%) 
 
The second hypothesis (Ho2b) is that there is no significant difference in 
persistence when comparing before and after PA/ST implementation. Persistence was 
measured using persistence days. Three acceptable gaps were used to determine 
persistence. Acceptable gaps of 30 days, 60 days, and 1.5 times the previous days supply 
were tested. Table 4.13 summarizes the results. 
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Table 4.13 Comparison of Persistence Before and After Prior Authorization 
 N = 34,048  
Pre-Prior 
Authorization 
Proportion of 
Persistent 
Patients 
N = 34,048 
Mean 
Persistence 
Days (SD) 
Post-Prior 
Authorization 
Proportion of 
Persistent 
Patients 
Mean 
Persistence 
Days (SD) Significance 
30 day gap 64%  117.7 (96.8)  63%  115.3 (96.3)  
t = 4.049;  
df = 34,047;  
p < 0.01  
60 day gap 75%  148.2 (104.6)  74%  147.8 (105.9)  
t = 0.686;  
df = 34,047;  
p = 0.493  
Gap 1.5 times 
previous days 
supply  58%  98.8 (88.6)  56%  97.6 (87.9)  
t = 2.253;  
df = 34,047;  
p = 0.024  
 
A paired t-test showed that the mean persistence days before the PA (117.7, SD = 
96.8) was slightly (but statistically significantly) higher than the mean persistence days 
after the PA (115.3, SD = 96.3) (t = 4.049; df = 34,047; p < 0.01) when an acceptable gap 
of 30 days was used. Therefore, this hypothesis was rejected. 
A paired t-test showed no significant difference in mean persistence days before 
the PA (148.2, SD = 104.6) and mean persistence days after the PA (147.8, SD = 105.9) 
(t = 0.686; df = 34,047; p = 0.493) when an acceptable gap of 60 days was used. 
Therefore, this hypothesis failed to be rejected. 
A paired t-test showed no significant difference in mean persistence days before 
the PA (98.8, SD = 88.6) and mean persistence days after the PA (97.6, SD = 87.9) (t = 
2.253; df = 34,047; p = 0.024) when an acceptable gap of 1.5 times the previous 
prescriptions’ days supply was used. Therefore, this hypothesis failed to be rejected. 
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Objective Three 
Multiple regression was used to test whether adherence measured by MPR in the 
pre-PA time period is a predictor of MPR in the post-PA time period while controlling 
for covariates (starting dose (index PRSD), mean dose (PRSD), age, mean copay, point 
of service, and brand of product). The dependent variable was MPR in the post-PA 
period. The independent variable was MPR in the pre-PA period.  
The variable entry method was used. Covariates were placed in block one and the 
independent variable in block two. Assumptions of constant variance, normality of 
residuals, and multicollinearity were checked. There is no pattern in the plot of the 
residuals versus the predicted values of the DV indicating constant variance. The plot of 
the residuals appears reasonably normal. Multicollinearity diagnostics indicate tolerance 
is not less than 0.1 for any IV and therefore multicollinearity is not present.  
Model one includes only the covariates and indicates at least one of the covariate 
predictors is significantly related to the MPR in the post-PA time period (R2 = 0.051, R2adj 
= 0.051, F(11,25594) = 125.81, p < 0.001). This model, overall, is able to explain 5.1% 
of the variability in MPR post-PA.  
Model two contains the covariates and MPR pre-PA as the predictor and indicates 
at least one of the predictors is significantly related to the MPR in the post-PA time 
period (R2 = 0.16, R2adj = 0.159, F(12,25593) = 405.77, p<0.001). This model, overall, is 
able to explain 15.9% of the variability in MPR post-PA. MPR in the pre-PA time period 
was a significant positive predictor of post-PA MPR (B = 0.348, β = 0.338 , t(25,593) = 
57.5, p < 0.001. This means for every increase in the pre-PA MPR by 1, the post-PA 
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MPR increases by 0.348. Therefore, the hypothesis is rejected. There is a significant 
difference in adherence before and after PA/ST implementation while controlling for 
covariates.  
Objective Four 
Multiple regression was used to test whether persistence measured by persistence 
days in the pre-PA time period is a positive predictor of persistence in the post-PA time 
period while controlling for covariates (starting dose (index PRSD), mean dose (PRSD), 
age, mean copay, point of service, and brand of product). The dependent variable was 
persistence days in the post-PA period. The independent variable was persistence days in 
the pre-PA period. Persistence days associated with a gap of 30 days are reported. 
The variable entry method was used. Covariates were placed in block one and the 
independent variable in block two. Assumptions of constant variance, normality of 
residuals, and multicollinearity were checked. There is no pattern in the plot of the 
residuals versus the predicted values of the DV indicating constant variance. The plot of 
the residuals appears somewhat normal. Multicollinearity diagnostics indicate tolerance is 
not less than 0.1 for any IV and therefore multicollinearity is not present.  
Model one includes only the covariates and indicates at least one of the covariate 
predictors is significantly related to persistence days in the post-PA time period (R2= 
0.009, R2adj = 0.009, F(11,34036) = 28.27, p < 0.001) when using a 30 day gap. This 
model, overall, is able to explain 0.9% of the variability in persistence days post-PA. The 
results of model one were robust to changes in the allowable gap (30 days, 60 days, and 
1.5 times the previous prescriptions’ days supply).  
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Model two contains the covariates and persistence days pre-PA as the predictor 
and indicates at least one of the predictors is significantly related to the MPR in the post-
PA time period (R2 = 0.129, R2adj = 0.129, F(12,34045) = 419.53, p <0.001). This model, 
overall, is able to explain 12.9% of the variability in persistence post-PA. Persistence 
days in the pre-PA time period was a significant positive predictor of post-PA persistence 
days (B = 0.348, β = 0.350, t(34,045) = 68.42, p < 0.001. This means for every increase 
in pre-PA persistence days by one, the post-PA persistence days increase by 0.348. The 
results of model one were robust to changes in the allowable gap (30 days, 60 days, and 
1.5 times the previous prescriptions’ days supply). Therefore, the hypothesis is rejected. 
There is a significant difference in persistenc before and after PA/ST implementation 
while controlling for covariates.  
Objective Five 
In the post-PA period, 19.1% of the 34,048 patients switched products at least 
once from their index post-period product. Restarting behaviors occurred in 23.4% of the 
34,048 paired patients. Cycling occurred in 18.6% of paired patients. The goal of 
objective five is to predict the likelihood of switching, restarting, and cycling patterns 
post PA/ST, by product type, overall average daily dose, point of service, and age group 
using logistic regression. Table 4.17 summarizes the results of the logistic regression. 
Tables 4.14, 4.15, and 4.16 summarize the results of the logistic regression for switching, 
restarting, and cycling respectively. 
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Table 4.14 Logistic Regression Results for Objective Five - Switching  
Product Type – Androgel Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Androderm 0.850 0.739-0.978 8.899 0.003 
Axiron 0.703 0.608-0.814 38.473 < 0.01 
Fortesta 0.264 0.199-0.349 149.557 < 0.01 
Striant 0.355 0.092-1.366 3.921 0.048 
Testim 0.804 0.721-0.895 27.183 < 0.01 
Product Type – Fortesta Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Androgel 3.225 2.370-4.389 95.803 < 0.01 
Androderm 3.794 2.865-5.024 149.557 < 0.01 
Axiron 2.668 1.955-3.641 66.084 < 0.01 
Striant 1.347 0.341-5.326 0.311 0.577 
Testim 3.049 2.270-4.095 94.781 < 0.01 
Overall Average Daily Dose 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Overall 
Average Daily 
Dose 0.899 0.823-0.981 9.917 0.002 
Point of Service – Retail Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Mail Order 0.852 0.763-0.951 13.988 < 0.01 
Military 
Treatment 
Facility 2.203 2.034-2.385 654.235 < 0.01 
Age 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Age 0.989 00.986-0.992 91.029 < 0.01 
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Hypothesis H5oa states there is no significant difference in the likelihood of 
switching by product type. The first iteration of this test Androgel is the reference 
product. In the second iteration, Fortesta is the reference product. In the first iteration, the 
product type variable was dummy coded with Androgel as the reference product. The 
Hosmer-Lemeshow test of fit is not significant (χ2 = 0.000; df = 2, p = 1.000) indicating 
good model fit. The enter variable method was used. The chi-square test of the difference 
in fit between the null model and the model including the primary independent variable, 
product type, is significant (χ2 = 263.595; df = 5, p < 0.01). This suggests at least one 
predictor is related to switching status. 
The reference product is Androgel. Androderm (OR= 0.850; 99% CI= 0.39 – 
0.978; p=0.003), Axiron (OR= 0.703; 99% CI= 0.608 – 0.814; p<0.001), Fortesta (OR= 
0.264; 99% CI= 0.199 – 0.349; p<0.001), and Testim (OR= 0.804; 99% CI= 0.721 – 
0.895; p<0.001) were significant predictors. Striant was not significant (OR= 0.355; 99% 
CI= 0.092 – 1.366; p=0.048). Compared to Androgel, the chances of switching decrease 
by 15% for Androderm, 30% for Axiron, 74% for Fortesta, and 20% for Testim, 
therefore, the hypothesis is rejected for Androderm, Axiron, Fortesta, and Testim.  
In the second iteration, the product type variable was dummy coded with Fortesta 
as the reference product. The Hosmer-Lemeshow test of fit is not significant (χ2 = 0.000; 
df = 2, p = 1.000) indicating good model fit. The enter variable method was used. The 
chi-square test of the difference in fit between the null model and the model including the 
primary independent variable, product type, is significant (χ2 = 263.595; df = 5, p < 0.01). 
This suggests at least one predictor is related to switching status. 
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The reference product is Fortesta. Androderm (OR= 3.794; 99% CI= 2.865 – 
5.024; p<0.001), Androgel (OR= 3.225; 99% CI= 2.370 – 4.389; p<0.001), Axiron (OR= 
2.668; 99% CI= 1.955 – 3.641; p<0.001), and Testim (OR= 3.049; 99% CI= 2.270 – 
4.095; p<0.001) were significant predictors. Striant was not significant (OR= 1.347; 99% 
CI= 0.341 – 5.326; p=0.577). Compared to Fortesta, the chances of switching increase by 
279.4% for Androderm, 222.5% compared to Androgel, 166.8% for Axiron, and 204.9% 
for Testim. Therefore, the hypothesis is rejected for Androderm, Androgel, Axiron, and 
Testim. 
Hypothesis Ho5b states there is no significant difference in the likelihood of 
switching by average daily dose. The Hosmer-Lemeshow test of fit is significant (χ2 = 
420.512; df = 6, p < 0.01) indicating a poor model fit. The enter variable method was 
used. The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, mean daily dose, is significant (χ2 = 10.002; 
df = 1, p < 0.01). This suggests mean daily dose is related to switching status. The odds 
of switching decrease as mean dose increases, however, these results should be 
interpreted with caution as there is a violation of assumptions. 
Hypothesis Ho5c states there is no significant difference in the likelihood of 
switching by point of service. The Hosmer-Lemeshow test of fit is not significant (χ2 = 
0.000; df = 1, p = 1.000) indicating good model fit. The enter variable method was used. 
The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, point of service, is significant (χ2 = 749.19; 
df = 2, p <0.01). This suggests at least one predictor is related to switching status. The 
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reference POS is retail. Mail order (OR=0.852; 99% CI=0.763 – 0.951; p<0.001) and 
MTF (OR= 2.203; 99% CI= 2.034 – 2.385; p<0.001) were significant predictors. 
Compared to retail, the chances of switching decrease by 14.8% at mail order and 
increase by 10.3% at the MTF. Therefore, the hypothesis is rejected for mail order and 
MTF. 
Hypothesis Ho5d states there is no significant difference in the likelihood of 
switching by age. The Hosmer-Lemeshow test of fit is significant (χ2 = 19.926; df = 8, p 
= 0.011) indicating a poor model fit. The enter variable method was used. The chi-square 
test of the difference in fit between the null model and the model including the primary 
independent variable, age, is significant (χ2 = 90.931; df = 1, p < 0.01). This suggests age 
is related to switching status. The odds of switching decrease as age increases, however, 
these results should be interpreted with caution as there is a violation of assumptions. 
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Table 4.15 Logistic Regression Results for Objective Five - Restarting  
Product Type – Androgel Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Androderm 1.016 0.883-1.169 0.087 0.768 
Axiron 0.970 0.843-1.115 0.317 0.573 
Fortesta 1.298 1.086-1.550 14.271 < 0.01 
Striant 1.239 0.479-3.207 0.338 0.561 
Testim 0.901 0.811-1.002 6.418 0.011 
Overall Average Daily Dose 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Overall 
Average Daily 
Dose 0.930 0.852-1.015 4.621 0.032 
Point of Service – Retail Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Mail Order 0.733 0.659-0.815 57.045 < 0.01 
Military 
Treatment 
Facility 1.204 1.107-1.310 32.280 < 0.01 
Age 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Age 0.995 0.992-0.998 21.602 < 0.01 
 
Hypothesis Ho5e states there is no significant difference in the likelihood of 
restarting by product type. The product type variable was dummy coded with Androgel as 
the reference product. The Hosmer-Lemeshow test of fit is not significant (χ2 = 0.000; df 
= 2, p = 1.000) indicating good model fit. The enter variable method was used. The chi-
square test of the difference in fit between the null model and the model including the 
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primary independent variable, product type, is significant (χ2 = 23.333; df = 5, p < 0.01). 
This suggests at least one predictor is related to restarting status. 
The reference product is Androgel. Fortesta (OR= 1.298; 99% CI =1.086 – 1.550; 
p<0.001), was a significant predictor. Androderm (OR=1.016; 99% CI=0.883 – 1.169; 
p=0.768), Axiron (OR= 0.970; 99% CI=0.843 – 1.115; p=0.573), Straint (OR=1.239; 99% 
CI =0.479 – 3.207; p=0.561), and Testim (OR=0.901; 99% CI=0.811 – 1.002; p=0.011) 
were not significant predictors. Compared to Androgel, the chances of restarting increase 
by 29.8% for Fortesta. The hypothesis is rejected for Fortesta. 
Hypothesis Ho5f states there is no significant difference in the likelihood of 
restarting by average daily dose. The Hosmer-Lemeshow test of fit is significant (χ2 = 
19.258; df = 6, p = 0.04) indicating a poor model fit. The enter variable method was used. 
The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, mean daily dose, is not significant 
(OR=0.930; 99% CI=0.852 – 1.015; p=0.032). This suggests mean daily dose is not 
related to restarting status and failure to reject the hypothesis.  
Hypothesis Ho5g states there is no significant difference in the likelihood of 
restarting by point of service. The Hosmer-Lemeshow test of fit is not significant (χ2 = 
0.000; df = 1, p = 1.000) indicating good model fit. The enter variable method was used. 
The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, point of service, is significant (χ2 = 118.163; 
df = 2, p <0.01). This suggests at least one predictor is related to switching status. The 
reference POS is retail. Mail order (OR=0.733; 99% CI =0.659 – 0.815; p<0.001) and 
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MTF (OR=1.204; 99% CI=1.107 – 1.310; p<0.001) were significant predictors. Compared 
to retail, the chances of switching decrease by 26.7% at mail order and increase by 20.4% 
at MTF and therefore, the hypothesis is rejected. 
Hypothesis Ho5h states there is no significant difference in the likelihood of 
restarting by age. Hypothesis H5b states there is no difference in restart status by average 
daily dose. The Hosmer-Lemeshow test of fit is significant (χ2 = 19.926; df = 8, p = 
0.011) indicating a poor model fit. The enter variable method was used. The chi-square 
test of the difference in fit between the null model and the model including the primary 
independent variable, age, is significant (OR=0.995; 99% CI=0.992 – 0.998; p<0.001). 
This suggests age is related to restarting status. The odds of restarting decrease as age 
increases; however, these results should be interpreted with caution as there is a violation 
of assumptions. 
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Table 4.16 Logistic Regression Results for Objective Five - Cycling 
Product Type – Androgel Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Androderm 1.010 0.870-1.174 0.031 0.861 
Axiron 1.215 1.053-1.402 12.250 < 0.01 
Fortesta 1.324 1.099-1.594 15.081 < 0.01 
Striant 0.659 0.204-2.129 0.838 0.360 
Testim 0.885 0.789-0.992 7.584 0.006 
Overall Average Daily Dose 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Overall 
Average Daily 
Dose 0.946 0.862-1.039 2.333 0.127 
Point of Service – Retail Reference 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Mail Order 0.564 0.550-0.636 150.129 < 0.01 
Military 
Treatment 
Facility 1.053 0.963-1.151 2.188 0.139 
Age 
 
Odds Ratio 
99% 
Confidence 
Interval Wald χ2 p-value 
Age 0.995 0.992-0.998 16.433 < 0.01 
 
Hypothesis Ho5i states there is no significant difference in the likelihood of 
cycling by product type. The product type variable was dummy coded with Androgel as 
the reference product. The Hosmer-Lemeshow test of fit is not significant (χ2 = 0.000; df 
= 2, p = 1.000) indicating good model fit. The enter variable method was used. The chi-
square test of the difference in fit between the null model and the model including the 
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primary independent variable, product type, is significant (χ2 = 38.552; df = 5, p < 0.01). 
This suggests at least one predictor is related to cycling status. 
The reference product is Androgel. Axiron (OR=1.215; 99% CI=1.053 – 1.402; 
p<0.001), Fortesta (OR=1.324; 99% CI=1.099 – 1.594; p<0.001), and Testim (OR=0.885; 
99% CI=0.789 – 0.992; p=0.006) are significant. Androderm (OR=1.010; 99% CI=0.870 – 
1.174; p=0.861) and Striant (OR=0.659; 99% CI=0.204 – 2.129; p=0.360) are not 
significant. Compared to Androgel, the chances of cycling increase 21.5% with Axiron, 
increase 32.4% with Fortesta, and decrease 11.5% with Testim. The hypothesis is 
rejected for Axiron, Fortesta, and Testim. 
Hypothesis Ho5j states there is no significant difference in the likelihood of 
cycling by average daily dose. The Hosmer-Lemeshow test of fit is significant (χ2 = 
13.643; df = 6, p = 0.34) indicating a poor model fit. The enter variable method was used. 
The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, mean daily dose, is not significant 
(OR=0.946; 99% CI=0.862 – 1.039; p=0.127). This suggests mean daily dose is not 
related to cycling status and failure to reject the hypothesis. 
Hypothesis Ho5k states there is no significant difference in the likelihood of 
cycling by point of service. The Hosmer-Lemeshow test of fit is not significant (χ2 = 
0.000; df = 1, p = 1.000) indicating good model fit. The enter variable method was used. 
The chi-square test of the difference in fit between the null model and the model 
including the primary independent variable, point of service, is significant (χ2 = 183.055; 
df = 2, p <0.01). This suggests at least one predictor is related to cycling status. The 
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reference POS is retail. Mail order (OR=0.564; 99% CI=0.550 – 0.636; p<0.001) was a 
significant predictor. MTF (OR=1.053; 99% CI=0.963 – 1.151; p=0.139) was not a 
significant predictor. Compared to retail, the chances of cycling decrease by 43.6% at 
mail order, therefore the hypothesis is rejected for retail. 
Hypothesis Ho5l states there is no significant difference in the likelihood of 
cycling by age. The Hosmer-Lemeshow test of fit is not significant (χ2 = 9.384; df = 8, p 
= 0.311) indicating good model fit. The enter variable method was used. The chi-square 
test of the difference in fit between the null model and the model including the primary 
independent variable, age, is significant (χ2 = 16.425; df = 1, p < 0.01). This suggests age 
is related to cycling status. Age (OR=0.995; 99% CI=0.992 – 0.998; p<0.001) was a 
significant predictor. The odds of cycling decrease by 0.2% for each additional year of 
age and therefore the hypothesis is rejected. 
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Table 4.17 Summary of Logistic Regression Results 
 Switch  Restart  Cycle  
Product type  
Androgel 
reference  
Yes – Compared to 
Androgel, the chance 
of switching 
decreases by 74% for 
Fortesta. 
(OR= 0.264; 99% 
CI= 0.199-
0.349;p=<0.01) 
Yes – Fortesta users 
had a 29.8% higher 
chance of restarting 
compared to 
Androgel. 
(OR= 1.298; 99% 
CI=1.086-1.550;p= 
<0.01) 
Yes – Compared to 
Androgel, Fortesta 
(32.4%) had higher 
chances of cycling 
(OR=1.324; 99% 
CI=;1.099-1.594, p= 
<0.01) 
Fortesta 
reference  
Compared to 
Fortesta, the chance 
of switching 
increases by 222.5% 
for Androgel. 
(OR= 3.225; 99% 
CI= 2.370-
4.389;p=<0.01) 
N/A  N/A  
Overall average daily 
dose  
No  No  No  
Point of service  Compared to retail, 
the chance of 
switching decreases 
by 14.8% at mail 
order (OR= 0.852; 
99% CI=0.763-
0.951;p= <0.01)and 
increases by 120.3% 
at MTF. (OR= 2.203; 
99% CI=2.034-
2.385;p= <0.01)  
Compared to retail, 
the chance of 
restarting decreases  
by 26.7% at mail 
order (OR= 0.733; 
99% CI=0.659-
0.815; p= <0.01) and 
increases by 20.4% 
at military treatment 
facility. (OR= 1.204; 
99% CI=1.107-
1.310;p= <0.01) 
Compared to retail, 
the chance of cycling 
decreases by 43.6% 
at mail order. 
(OR= 0.564; 99% 
CI=0.500-0.636;p= 
<0.01) 
Age  No  No  The chance of 
cycling decreases 
0.5% for each 
additional year of 
age. 
(OR= 0.995; 99% 
CI=0.992-0.998;p= 
<0.01) 
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Objective Six 
Objective six aims to compare the number of days from the expected end of the 
last prescription in the pre-PA period to the index prescription in the post-PA period (PA 
gap days) to the mean number of days for all the gap periods (other than the PA gap) in 
the paired group of patients. A paired-groups t-test showed that the mean number of PA 
gap days (94.0, SD = 100.5) was significantly higher than the mean gap period days (46.6, 
SD = 68.8) (t = 124; df = 34,047; p < 0.001) and therefore the hypothesis is rejected. 
CONCLUSION 
This concludes the reporting of the study results. The next chapter, the discussion, 
will provide additional context, meaning, and interpretation of the reported results. 
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Table 4.18 Study Objectives, Hypotheses, and Results 
 Objective 1: Describe medication costs, number of new users, number of 30-day equivalent prescriptions, 
proportion of prescriptions by pharmacy point of service, proportion of prescriptions by product, mean 
patient age, and mean daily dose before and after PA and ST program initiation in the DoD. 
Objective 2:  Compare adherence and persistence before and after PA/ST. 
Objectives/ 
hypotheses 
Dependent 
variables 
Measurement 
level 
Independent 
variables 
Measurement 
level 
Statistical 
analysis Result 
Ho2a: There is 
no significant 
difference in 
mean adherence 
before and after 
PA/ST 
implementation
. 
MPR Continuous PA/ST 
status 
 
 
Dichotomous Paired t-test Reject 
Ho2b: There is 
no significant 
difference in 
mean 
persistence 
before and after 
PA/ST 
implementation
. 
Persistence 
days 
Continuous PA/ST 
status 
 
 
Dichotomous Paired t-test 30 day gap: 
Reject 
60 day gap: 
Fail to reject 
1.5 times 
previous day 
supplys gap: 
Fail to reject 
Objective 3:  Compare adherence before and after PA/ST while controlling for covariates (starting dose, 
overall average daily dose, age, copay, point of service, and product type). 
Ho3: There is no 
significant 
difference in 
adherence 
before and after 
PA/ST 
implementation 
while 
controlling for 
covariates. 
MPR Continuous PA/ST 
status 
 
Covariates 
 
Dichotomous Multiple 
regression 
Reject 
Objective 4:  Compare persistence before and after PA/ST while controlling for covariates (starting dose, 
overall average daily dose, age, copay, point of service, and product type). 
Ho4: There is 
no significant 
difference in 
persistence 
before and after 
PA/ST 
implementation 
controlling for 
covariates. 
Persistence 
days 
Continuous PA/ST 
status 
 
Covariates 
 
Dichotomous Multiple 
regression 
Reject 
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Table 4.18 Continued 
Objective 5: To compare switching, restarting, and cycling patterns post PA/ST, by product type, overall 
average daily dose, point of service, and age. 
Objectives/ 
hypotheses 
Dependent 
variables 
Measurement 
level 
Independent 
variables 
Measurement 
level 
Statistical 
analysis Result 
Ho5a: There is 
no significant 
difference in 
the likelihood 
of switching by 
product type. 
Switch 
status 
Dichotomous Product 
type 
Categorical Logistic 
regression 
 
Reject 
Ho5b: There is 
no significant 
difference in 
the likelihood 
of switching by 
average daily 
dose. 
Switch 
status 
Dichotomous Overall 
average 
daily dose 
Continuous Logistic 
regression 
Fail to reject 
Ho5c: There is 
no significant 
difference in 
the likelihood 
of switching by 
point of service. 
Switch 
status 
Dichotomous Point of 
service 
Categorical Logistic 
regression 
 
Reject 
Ho5d: There is 
no significant 
difference in 
the likelihood 
of switching by 
age. 
Switch 
status 
Dichotomous Age Continuous Logistic 
regression 
Fail to reject 
Ho5e: There is 
no significant 
difference in 
the likelihood 
of restarting by 
product type. 
Restart 
status 
Dichotomous Product 
type 
Categorical Logistic 
regression 
Reject 
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Table 4.18 Continued 
Objective 5: To determine switching, restarting, and cycling patterns post PA/ST, by product type, 
overall average daily dose, point of service, and age. 
Objectives/ 
hypotheses 
Dependent 
variables 
Measurement 
level 
Independent 
variables 
Measurement 
level 
Statistical 
analysis Result 
Ho5f: There is 
no significant 
difference in 
the likelihood 
of restarting by 
average daily 
dose. 
Restart 
status 
Dichotomous Overall 
average 
daily dose 
Continuous Logistic 
regression 
Fail to 
reject 
Ho5g: There is 
no significant 
difference in 
the likelihood 
of restarting by 
POS. 
Restart 
status 
Dichotomous Point of 
service 
Categorical Logistic 
regression 
 
Reject 
Ho5h: There is 
no significant 
difference in 
the likelihood 
of restarting by 
age. 
Restart 
status 
Dichotomous Age Continuous  Logistic 
regression 
Fail to 
reject 
Ho5i: There is 
no significant 
difference in 
the likelihood 
of cycling by 
product type.  
Cycling 
status 
Dichotomous Product 
type 
Categorical Logistic 
regression 
 
Reject 
Ho5j: There is 
no significant 
difference in 
the likelihood 
of cycling by 
average daily 
dose. 
Cycling 
status 
Dichotomous Overall 
average 
daily dose 
Continuous Logistic 
regression 
Fail to 
reject 
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Table 4.18 Continued 
Objective 5: To determine switching, restarting, and cycling patterns post PA/ST, by product type, 
overall average daily dose, point of service, and age. 
Objectives/ 
hypotheses 
Dependent 
variables 
Measurement 
level 
Independent 
variables 
Measureme
nt level 
Statistical 
analysis 
Result 
H5k: There is no 
significant 
difference in 
the likelihood 
of cycling by 
point of service. 
Cycling 
status 
Dichotomous Point of 
service 
Categorical Logistic 
regression 
 
Reject 
H5l: There is no 
significant 
difference in 
the likelihood 
of cycling by 
age. 
Cycling 
status 
Dichotomous Age Continuous Logistic 
regression 
Reject 
Objective 6: Compare mean gap days between the last prescription in pre-period and the first 
prescription in the post-period to average gap days overall. 
H6: There is no 
significant 
difference in 
gap days during 
PA/ST 
implementation 
and overall 
mean gap days. 
Gap days 
during 
PA/ST 
implementat
ion 
Continuous Mean gap 
days  
Continuous Paired t-
test 
Reject 
DoD = Department of Defense 
PA = prior authorization 
ST = step therapy 
MPR = medication possession ratio 
TBD = to be determined 
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Chapter 5: Discussion and Conclusions 
INTRODUCTION 
This is the first known study to examine the Department of Defense (DoD) prior 
authorization (PA) and step therapy (ST) programs for testosterone products. Results 
show a decrease in testosterone utilization and costs, as well as possible impacts on 
testosterone use behaviors. The results chapter presented the overall findings and specific 
objective findings of this study. This chapter, aims to provide context and meaning to 
those results. First, the findings of this study will be interpreted. Second, there is a 
discussion of study limitations and a conclusion including recommended future actions 
and follow-up research.   
DISCUSSION OF RESULTS 
Overall Results 
Prior to the implementation of the PA program, testosterone use in the DoD was 
steadily increasing, which is consistent with studies in other populations.53,87,88 The 
implementation of the PA for testosterone in the DoD was designed to ensure safe and 
appropriate use of testosterone products. Of the 60,512 patients with claims before the 
implementation of the PA, 56.3% met the PA criteria and had a successful claim for an 
included product after PA implementation. Those 60,512 patients represent 77.0% of the 
overall 78,623 study subjects. Overall, 52,159 (66%) of the 78,623 patients had 
successful claims after PA implementation. 
In general these results are consistent with other studies evaluating the impacts of 
PA and ST. One study in Canada found that government-imposed restrictions on 
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testosterone use led to a 27.9% decrease in testosterone utilization rates in the first six 
months of prescribing restrictions.102 Despite these restrictions, within a year, rates of 
testosterone use returned to historically high levels, primarily driven by topical 
products.102 In the year following implementation of the DoD PA and ST programs, 
utilization of testosterone did decrease, but the trend following the implementation year is 
not known. Sustained management of testosterone utilization over time is key to the 
effectiveness of the PA and ST programs, and warrants further investigation.  
Demographics 
In this study, 50% of patients were 45 to 64 years old at index which is consistent 
with a previous study showing that in men using topical testosterone, 54% of the patients 
were age 50-64.5 The prevalence of low testosterone increases with age; however, in this 
and other studies the majority of the patients are younger than 65 years old.5,10,88 
Clinical 
Other studies have examined product mix, dose, and duration of therapy in 
testosterone therapy. Baillargeon et al. found that the majority of testosterone patients 
were using a topical product.53 In another study, Androgel was the initiating product in 
75% of patients in 2009.5 From 2010 to 2012, 51% of all testosterone patients in Ontario, 
Canada used a topical agent.102 In this study, Androgel was the index product for 53.6% 
of patients. In this and other studies, Androgel dominated product market share. 
Index testosterone dose was, on average, proportionate to the recommended 
starting dose according to manufacturers in this study and tended to not escalate. Previous 
studies found that 78.6% of patients initiated at the standard dose and in general tended to 
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not experience dose escalation. In patients that remained on therapy over time, the 
proportion of patients on escalated doses did increase.5 Lack of dose titration is a possible 
contributor to discontinuation of therapy as patients may not be reaching a dose that is 
adequate to address symptoms. Additionally, it is known that testosterone levels decline 
with age, and studies have shown that age may independently be linked to the symptoms 
of low testosterone, not just the testosterone levels themselves. Therefore, disease 
escalation may also play a role in therapy failure.103 
Previous studies found a large number of patients receiving only one prescription. 
In this study, in the overall group, 21% of patients received only one prescription. Other 
studies found 18.63% had only one prescription and that only approximately 33% of 
patients continued therapy longer than two months.5,53 
Results of Objectives 
Here, the results of each of the six objectives are discussed. 
Objective One 
The first objective is to describe the overall effects of the PA and ST. The PA and 
ST for were successful at decreasing costs and utilization of testosterone. The process 
was successful at shifting patients to the preferred agent and eliminating potentially 
inappropriate use by patients that did not meet treatment criteria. The overall number of 
utilizers decreased, and additionally the number of new users decreased. The number of 
utilizers may not have decreased as drastically as it did had there not been no-
grandfathering conditions. This is important for future implementation of formulary 
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decisions. It is important to note that this type of restriction is still not routinely utilized 
by the DoD in formulary management. 
A decrease in the proportion of the recommended starting dose (PRSD) from 1.03 
to 0.92 does not represent a clinically relevant decrease in dose, but indicates a trend that 
after the PA and ST patients did not use as high of a dose as in the pre-period. Doses are 
adjusted by increments of 50-100% of the PRSD, and therefore a larger change would be 
needed to be clinically relevant. The utilization of mail order increased in both volume 
and proportion of prescriptions. Retail utilization decreased and MTF utilization 
increased. The lowest copays are available at the military treatment facility (MTF) and 
through mail order.   
Objective Two 
Objective two compares adherence and persistence before and after the 
implementation of the PA and ST criteria. Medication possession ratio (MPR) and 
persistence with a 30 day gap were significantly different before and after 
implementation. While MPR was higher before implementation, the decrease in MPR 
was small (0.0081). The proportion of patients with an MPR greater than 0.80 decreased 
by 1.76%, which is also a small change. Therefore, while MPR was statistically 
significantly different, these differences are not relevant clinically. Previous studies also 
found low adherence rates. In one study, the overall average MPR was 56% over six 
months.5 In this study the adherence rate ranged from 53.46% to 55.22%.  
Persistence days were statistically significantly lower after the implementation 
with a 30 day gap, but the difference is not clinically relevant. The difference was only 
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2.4 days. The sensitivity analyses were not statistically significant. This shows that it is 
important in persistence studies to perform sensitivity analysis for the length of the gap 
used. Previous studies found the length of therapy ranged from 137 to 146 days.5 These 
results are similar to this study, which depending on gap tested, length of therapy ranged 
from 97.6 to 148.2 days. Use of a shorter, unacceptable gap (30 days) led to higher non-
persistent rates and shorter average length of therapy. 
The patients that successfully received prior authorization and continued 
testosterone therapy did not have clinically relevant changes in MPR and persistence 
overall. There were, however, other persistence related findings which are discussed later 
in this section. 
Objective Three 
Objective three examines whether or not MPR in the pre-PA time period can 
predict MPR in the post-PA time period while controlling for other variables (starting 
dose (index PRSD), mean dose (PRSD), age, mean copay, point of service, and brand of 
product). The pre-period MPR and other variables were able to predict 15.9% of the 
variability in the post-period MPR, and pre-MPR was a significant positive predictor of 
the post-MPR. The addition of pre-MPR to the model improved the amount of variability 
explained by 10.8% beyond the other variables. While objective two found that the MPRs 
were significantly different in the two time periods (but not clinically significant), this 
objective shows how previous behavior could predict behavior following the PA 
implementation.  
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Objective Four 
Objective three examines whether or not persistence days in the pre-PA time 
period can predict persistence days in the post-PA time period while controlling for other 
variables (starting dose (index PRSD), mean dose (PRSD), age, mean copay, point of 
service, and brand of product). The pre-PA period persistence days and other variables 
were able to predict 12.9% of the variability in the post-PA period persistence days, and 
pre-PA period persistence days were a significant positive predictor of the post-PA period 
persistence days. The addition of pre-persistence days to the model improved the amount 
of variability explained by 12.0% beyond the other variables. Objective two found that 
the persistence days were significantly different in the two time periods (but not clinically 
significant). This is important because it quantifies what efforts to improve persistence 
may be able to influence. For every one additional persistence day in the pre-period, there 
are 0.348 additional days in the future time period. 
Objective Five 
Objective five examines switching, restarting, and cycling behaviors after the PA 
and ST implementation by product type, overall average daily dose, point of service, and 
age. In a previous study, 66.4% of patients discontinued therapy after two months and 
then 50% of those patients restarted. Only 5% of men who restarted switched to another 
product.5 In another study, at three months after initiation, 54% of topical patients and 
37% of injectable patients were still using a testosterone product. The majority (60%) of 
patients using topical therapy had cyclical behavior. There were no meaningful 
differences between cyclical users by age, physician specialty, copays, diagnosis, 
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comorbidities, and the use of phosphodiesterase-5 (PDE-5) inhibitors during testosterone 
therapy. 7  
In this study, the implementation of PA and ST programs shifted patients to 
Fortesta, the preferred formulary agent. This study specifically isolated the fact that a PA 
and ST program was implemented, so those switches in product are attributable to a 
change in benefit design. Fortesta went from 5% of prescription volume to 70% of 
prescription volume after the PA and ST. After patients successfully navigated the PA 
and ST therapy, 19.1% had at least one additional therapy switch which was not 
attributed to the program implementation. Additional research is needed to investigate the 
characteristics and product mix involved in these switches.  
Androgel patient were the most likely to switch products after the PA and ST. 
Fortesta patients were the least likely to switch products after the PA and ST. This is 
expected because Fortesta was the preferred product and had the lowest copay and fewest 
administrative barriers. Additional research is needed to determine clinically if the 
patients on Fortesta had better outcomes compared to the Androgel patients that may also 
have contributed to the likelihood of switching. Switching could not be conclusively 
predicted by dose. Previous studies have shown that as patients discontinue testosterone 
therapy, the overall average dose increases, indicating that those patients that continue 
therapy tend to increase their dose over time. Also, escalation of dose was predictive of 
continuation of therapy.5 This study was unable to demonstrate a predictive relationship 
between dose and switching. 
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Compared to retail patients, patients at the MTF were 120.3% more likely to 
switch products. This may be attributable to the mix of provider type represented by each 
point of service (POS), but that information is not known in this study. MTF pharmacies 
do not have an automated process to implement formulary changes, whereas Express 
Scripts, Incorporated (ESI) automates the adjudication and approval of PA and ST. MTF 
pharmacists may have been slower to fully implement the PA and ST, and switches to 
Fortesta may have occurred after the implementation date leading to a higher likelihood 
of switching at MTF.  
Age was not a reliable predictor of switching. A recent study found that age and 
testosterone levels are confounding variables in the presence of low testosterone 
symptoms. Therefore, if testosterone levels are treated adequately and to goal, age is no 
longer a relevant indicator of disease severity.103 This study did not include testosterone 
levels, but follow-up research may show that the actual patient testosterone level would 
predict medication use behaviors. Dose was also not predictive and appeared to remain 
stable throughout the study period, which further supports that the appropriateness of 
therapy for each individual patient and testosterone levels may be driving behaviors.  
Restarting behaviors occurred in 23.39% of the 34,048 paired patients. Whether 
or not the patient restarted represents two concepts. First, that that patient had a break in 
therapy of greater than 30 days. Second, that patient chose to pursue therapy even after 
discontinuation. It can be seen as a negative that there is a break in therapy, but the fact 
that the patient restarted is a positive. This information is usually not captured in 
persistence studies. The fact that so many patients restarted (23.9%) indicates there is 
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more to how patients use testosterone than just discontinuation rates. The following 
section discusses factors that predict restarting behaviors. 
Patients on Fortesta were 29.8% more likely to restart compared to patients on 
Androgel. The other products were not significant predictors of switching. Further 
research is needed to understand why Fortesta patients were more likely to restart. It may 
be that patient satisfaction was higher with Androgel and they never had a break in 
therapy, or patients had breaks but valued therapy enough to return. 
Dose was not a significant predictor of restarting, but pharmacy POS was. Mail 
order was less likely to restart compared to retail, and MTF was more likely to restart 
compared to retail. Mail order may have been the least likely to restart because the filling 
procedures are the least immediate. Patients must wait for the medication to arrive. Also, 
testosterone is a controlled substance, and a new prescription is required every six 
months. Therefore, additional steps are needed to restart therapy at mail order, and 
impulsive restarts would be reduced. 
As age increases, the odds of restarting decrease. It is known that testosterone 
levels decrease with age, and patients may become more willing to accept low 
testosterone symptoms as the natural progression of aging. Additional research is needed 
in this area to determine if adequate treatment influences restart rate based on age and if 
these differences are clinically significant. 
Cycling occurred in 18.60% of all patients. Cycling patients are important 
because they are not detected in traditional persistence studies, but they represent a 
population that has continuous exposure to testosterone which has implications for safety 
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and behavioral studies. Labeling a single prescription an exposure may not be accurate, 
and categorizing patients discontinued after one therapy gap lacks inclusion of those 
patients that cycle. 
Product was a significant predictor of cycling. Fortesta patients were 32.4% more 
likely to cycle compared to Androgel patients. Additional analysis of these patients 
would reveal whether or not the Fortesta patients are more likely to cycle because they 
are more likely to have gaps in therapy, or if there is an unknown factor contributing to a 
intermittent treatment cycle.  
Dose was not predictive of cycling behavior. Patients that cycle are exhibiting 
behavior that indicates they have intermittent need or desire for treatment. Dose is unique 
to each individual patient’s clinical situation. Actual testosterone levels should be 
evaluated as a potential predictor of cycling behavior. 
Compared to retail, the odds of cycling decrease by 43.6% at mail order and MTF 
is not significantly different from retail. Mail order may be more difficult for patients to 
obtain a prescription after a break in therapy. A new prescription must be transmitted and 
the patient has to wait for delivery. This type of service is not conducive to impulsive or 
intermittent therapy. 
Age was a statistically significant predictor of cycling, but age may not be a 
meaningful predictor. The odds of cycling decrease with each year of age, but only by 
0.2%. While the trend is useful, and supports that the odds of restarting also decrease 
with age, the actual quantification of the odds are small. It is intuitive, however, that 
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patients would be less likely to cycle because they are also less likely to pursue therapy at 
all. 
Objective Six 
The final objective sought to examine the number of days (gap days) from the end 
of the last pre-PA prescription to the first post-PA prescription. PA gap days were 
significantly longer than mean gap days. This indicates that on average the longest period 
between prescriptions occurred immediately following the implementation of the PA and 
ST. This indicates that the presence of a PA and ST was related to the longest period of 
time between prescriptions. This information is key for two reasons. First, this signals the 
need for persistence studies to be informed by the formulary status and changes for each 
product. Second, PA and ST programs with no grandfathering may have longer gap days 
than those with grandfathering, and the implications of these differences are not known. 
Patients spent longer between prescriptions after the PA than the average of their other 
gaps. This information is needed to understand the actual factors that influence adherence 
and persistence. 
Limitations 
The following discussion of limitations provides the framework by which the 
study results should be interpreted. Retrospective, claims based studies have multiple 
inherent limitations and there are additional limitations specific to this study. 
 The data used in this study are comprised of pharmacy claims information in the 
DoD Pharmacy Data Transaction System (PDTS).  These data were not expressly 
collected for use in this type of study, but with appropriate steps, may be useful. One 
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major issue with these data is the potential for poor data integrity. For example, 
individual pharmacies may have erroneously entered incorrect information such as 
incorrect days supply or quantity. To minimize the effect of outliers or unreliable data, an 
analysis of outliers was conducted and values that could be reasonably managed were 
adjusted. The DoD is aware of these data integrity issues from MTF pharmacies and 
employs extensive efforts to correct and prevent incorrect data submission in the 
pharmacy claims. Overall, 21,779 quantity adjustments were made. Of those adjustments, 
99.1% occurred in claims from MTFs. In general, these adjustments accounted for 
discrepancies in package sizes. 
 There are known inaccuracies in the PDTS data for costs. This study does not 
account for the additional refunds provided by manufacturers at retail pharmacies, and 
therefore retail costs are relatively correct but not refund-adjusted. There is also potential 
for cost inaccuracies at the MTFs, however, relative reductions in costs are reliable. 
 Claims data cannot account for the patient that either used alternative health 
insurance (non-DoD) payment methods or paid cash for prescriptions. There are multiple 
potential situations this could occur. First, if patients encountered the PA and ST process 
and did not pursue the prescription, there is no record of this attempt. Those patients may 
have received the prescription using other insurance or cash payment.  
 In addition to the limitations present in claims studies, this study has specific 
design limitations. First, potentially important information may have been excluded. A 
longer study period, inclusion of all types of testosterone, and inclusion of other payment 
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types (other insurance or cash payment) would allow for a broader evaluation of 
testosterone use patterns.  
Second, other events that occurred during the study period may have influenced 
the results. At the time of the study, there were media reports on  safety issues of 
testosterone use. The Food and Drug Administration (FDA) recommended avoiding 
testosterone therapy in patients with low testosterone due to aging and also emphasized 
potential cardiovascular risks in testosterone therapy. At the same time, robust marketing 
campaigns touted the benefits of treating low testosterone in a general campaign with a 
wide audience.  
During the study period, changes were made to the DoD copay structure. On 
February 1, 2013, copays for brand name and non-formulary agents increased at both 
retail and mail order pharmacies. Patients may have chosen to forgo testosterone therapy 
at the higher copays. After the copay changes, injectable generic testosterone was the 
least expensive testosterone option.  
In terms of generalizability, the DoD population may not be comparable to other 
populations. Additionally, the ‘no grandfathering’ aspect of the DoD PA and ST may 
have created a stricter environment for the PA and ST to be applied that may not occur in 
other programs. Because even established patients were held to the new criteria, 
additional patients could have discontinued therapy. Finally, the presence of statistically 
significant results using large databases may not translate into significant clinical results.  
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RECOMMENDATIONS 
This section presents recommendations resulting from this study. 
Recommendations for the military health system (MHS) specifically and general 
recommendations are described. 
MHS Recommendations 
New Drugs to Market and Potential Cost Threats 
When new products were launched prior to August 26, 2013, they were 
automatically placed on the Uniform Formulary (UF). This means new, brand name 
drugs were available at the brand copay immediately and usually without restriction. This 
study shows how this particular policy can have negative financial consequences if 
utilization and costs are not actively managed. By the time the PA and ST were in place, 
many patients had already received prescriptions that were possibly inappropriate. The 
National Defense Authorization Act of 2015 created a program to classify certain newly 
approved drugs as non-formulary until they can be reviewed by the Pharmacy and 
Therapeutics (P&T) Committee.104 This effort will address a portion of the immediate 
financial risks after a medication launches, however, the results of this program are yet to 
be seen. Programs that allow for proactive, swift, flexible responses to concerning drugs 
trends are needed. 
Continue to Improve Data Integrity 
MTF pharmacies have recognized, extensive issues with data integrity. Multiple 
programs and efforts are in place to manage these issues. Researchers using DoD data 
should be aware of these issues and adjust study design and interpretation accordingly.  
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General Recommendations 
Interpret Adherence/Persistence Studies with Caution if Benefit Design Unknown 
This study is the only known study to evaluate adherence and persistence for 
certain testosterone products specifically in the presence of PA and ST programs. Other 
studies did not include the formulary status of each agent or the presence of potentially 
restrictive formulary benefit design programs. This study shows that these formulary 
guidelines and restrictions should be considered in evaluations of adherence and 
persistence as the actual patient behavior may be caused by changes to benefit design.  
Use Caution Interpreting Testosterone “Exposure” 
Studies that evaluate the safety of exposure to a medication must make 
assumptions about what constitutes exposure. In many testosterone studies, patients fail 
to continue beyond six months. In studies evaluating safety, it would be prudent to 
examine how long the patient persisted on therapy, as around 20% of patients do not 
continue beyond one prescription, and that exposure risk is likely not equivalent to those 
patients that continued on therapy for longer periods of time.  
FUTURE RESEARCH 
Additional research is needed in the areas of testosterone therapy (TTh) and the 
policy and impacts of benefit design.  
Testosterone 
One of the limitations of this study was the length of the study. Further study of 
testosterone therapy over a longer period of time is recommended. Evaluating dose over 
time, any product changes over time, and in patients that are essentially committed to 
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therapy, or continue using it for  at least 12 months, the actual length of therapy is 
important to know. Also, further evaluation of those short term patients, those that filled 
only one or two prescriptions, and greater understanding of why they initiated and why 
they discontinued should be pursued. 
Patients using concomitant PDE-5s may experience improved sexual symptoms 
above and beyond improvements attributable to testosterone alone. For this reason, 
patients using both PDE-5s and testosterone may have different treatment patterns. These 
patients should be identified and isolated in future studies. 
 The absence of baseline and follow-up labs in testosterone therapy may signal a 
lack of follow-up and potentially dose titration in general. Also, no actual labs or 
evidence of labs were collected. The word of the clinician was accepted to be adequate. 
Further information is needed to know if patients truly only used testosterone for the 
FDA indicated conditions. 
Lastly, the number of patients using Low-T clinics is unknown. These clinics 
offer access to injectable testosterone, labs, and management with or without insurance 
coverage. Little is known about this population of testosterone patients. 
Benefit Design 
The literature review previously stated that additional studies are needed evaluate 
the intended and unintended consequences of PA or ST programs. This study found that 
these processes may have contributed to non-persistence. There were 8,646 patients that 
did not successfully receive a prescription after the PA implementation that were on 
therapy prior to the PA implementation. Additional research is needed to evaluate the 
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unintended consequences of the PA for these patients. These patients discontinued 
therapy at the point of implementation, but the reason for discontinuation is unknown. 
Whether PA contributes to non-persistence in other medication classes, in those PA or ST 
programs that do allow grandfathering, and those outside the DoD system requires further 
investigation. In addition, it is unknown whether the reductions in utilization and costs 
are sustained beyond the first year after implementation.  
CONCLUSIONS 
This study adds to the existing testosterone use literature, specifically how PA and 
ST programs influence testosterone use behaviors. The effectiveness and impact of 
testosterone benefit design will inform future DoD formulary decisions and deepen 
understanding of testosterone use behaviors and how patients are impacted by benefit 
design. Additional research in this area is needed to explore how testosterone use occurs 
over time, how no-grandfathering programs differ from grandfathering programs, and 
enhance understanding of how benefit designs can be incorporated into adherence and 
persistence studies.  
Furthermore, this study examined switching, restarting, and cycling behaviors in 
the context of formulary management programs. There is evidence these programs 
influenced all three behaviors. Previous switching studies did not account for benefit 
design, yet this study found benefit design directly influenced switching behaviors as 
patients were switched to the preferred formulary agent. Discontinuation, restarting, and 
cycling were also driven by the implementation of the PA/ST. Of the patients established 
on testosterone prior to PA/ST, 56.3% successfully continued therapy after the PA/ST 
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implementation. Without considering benefit design in this study, the discontinuation rate 
may have been attributed to other variables. Additionally, patients that were successful at 
meeting PA/ST criteria had the longest break in therapy immediately following PA/ST 
implementation indicating the benefit design may have triggered restarting behaviors.   
Testosterone deficiency is an important health condition that impacts millions of 
men. Treating testosterone deficiency is costly and controversial. More information is 
needed on how patients use testosterone and the consequences of treatment. This study 
uncovers additional factors to be considered and identifies important research initiatives 
for the future.  
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APPENDICES 
APPENDIX A: INCLUDED TESTOSTERONE FORMS 
Form Brand Name Strength Starting Dose Maintenance 
Dose 
How Supplied (NDC and 
product description) 
Gel Androgel23 1% 
 
25 mg in 2.5g 
packet 
 
50 mg in 5g 
packet 
50 mg (either 2, 
25 mg packets 
or 1, 50 mg 
packet) applied 
once in the AM 
If testosterone 
levels are below 
normal range, 
increase from 
50 to 75 mg or 
75 mg to 100 
mg as directed 
by physician. 
If levels above 
normal range, 
decrease dose. 
If sustained 
doses of 50 mg 
are needed, 
discontinue use. 
0051-8425-30  
30, 25 mg packets 
0051-8450-30 
30, 50 mg packets 
Gel Androgel22 1.62% 
 
20.25 mg in 
1.25g packet 
 
40.5 mg in 2.5g 
packet 
40.5 mg (1 
packet) applied 
once in the AM 
Adjusted based 
on pre-dose 
testosterone 
levels: 
< 350 ng/dL: 
Add 20.25 mg 
per day 
350 ng/dL to 
750 ng/dL: No 
change 
> 750 ng/dL: 
Decrease by 
2.25 mg per day 
0051-8462-12  
Unit dose 20.25 mg packet 
0051-8462-31 
30, 20.25 mg packets 
0051-8462-01 
Unit dose 40.5 mg packet 
0051-8462-30 
30,40.5 mg packets 
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Form Brand Name Strength Starting Dose Maintenance 
Dose 
How Supplied (NDC and 
product description) 
Gel Androgel 
Pump23 
1% (12.5 
mg/actuation)  
50 mg (4 pump 
actuations) 
applied once in 
the AM 
If testosterone 
levels are below 
normal range, 
increase from 
50 mg to 75 mg 
or 75 mg to 100 
mg as directed 
by physician. 
If levels above 
normal range, 
decrease dose. 
If sustained 
doses of 50mg 
are needed, 
discontinue use. 
0051-8488-88 
2, 75 g pump (each pump 
dispenses 60 actuations) 
Gel Androgel 
Pump22 
1.62% (20.25 
mg/actuation) 
40.5 mg (2 
pump 
actuations) 
applied once in 
the AM 
Adjusted based 
on pre-dose 
testosterone 
levels: 
< 350 ng/dL: 
Add 20.25 mg 
per day 
350 ng/dL to 
750 ng/dL: No 
change 
> 750 ng/dL: 
Decrease by 
2.25 mg per day 
0051-8462-33 
88 g pump (60 actuations) 
Gel Fortesta27 10 mg/actuation 
(1%) 
40 mg (4 pump 
actuations) 
applied once in 
the AM 
Dose range is 
10 mg to 70 mg 
depending on 
pre-dose 
testosterone 
levels 
63471-183-16 
1 canister 
63481-183-17 
2 canisters 
63481-183-18 
3 canisters 
Gel Testim25 50 mg/5g 50 mg (one 
tube) applied 
once in the AM 
Dose range is 
50 mg (one 
tube) to 100 mg 
(2 tubes) 
depending on 
pre-dose 
testosterone 
levels 
66887-001-05 
30, 50 mg tubes 
Gel Vogelxo28 50 mg/5g 
 
50 mg in 1 
packet 
 
50 mg in 1 tube 
50 mg applied 
at the same time 
each day 
Dose range is 
50 mg  to 100 
mg depending 
on pre-dose 
testosterone 
levels 
0245-0871-05 
30, 50 mg tubes 
0245-0871-65 
1, 50 mg tube 
0245-0871-35 
30, 50 mg packets 
0245-0871-89 
1, 50 mg packet 
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Form Brand Name Strength Starting Dose Maintenance 
Dose 
How Supplied (NDC and 
product description) 
Gel Vogelxo 
Pump28 
12.5 
mg/actuation 
(75g of 1%) 
50 mg (4 pump 
actuations) 
applied at the 
same time each 
day 
Dose range is 
50 mg (4 pump 
actuations) to 
100 mg (8 
pump 
actuations) 
depending on 
pre-dose 
testosterone 
levels 
0245-0872-42 
2, 75 g pumps (each pump 
dispenses 60 actuations of 
12.5 mg) 
Buccal Striant30 30 mg 
mucoadhesive, 
buccal system 
30 mg every 12 
hours applied to 
gum region 
above incisor 
tooth 
No adjustment 
recommended 
by 
manufacturer. 
Recommend 
discontinuing if 
testosterone 
does not reach 
300 ng/dL to 
1050 ng/dL 
within four to 
twelve weeks 
52244-030-60 
6 blister packs 
10 buccal systems per pack 
Each buccal system delivers 
30 mg 
Transdermal 
patch, 24 hours 
Androderm26 2 mg/24 hours 
4 mg/24 hours 
(previously 
discontinued 
strengths of 
Androderm will 
also be 
included) 
One 4 mg/day 
system applied 
every 24 hours 
Recommend 
dose range of 2 
mg/24 hours to 
6 mg/24 hours 
depending on 
pre-dose 
testosterone 
levels 
52544-076-60 
60, 2 mg systems  
52544-077-30 
30, 4 mg systems 
Transdermal 
solution 
Axiron69 30 mg/actuation 60 mg (2 pump 
actuations) 
applied once 
per day 
Recommend a 
dose range of 
30 mg to 120 
mg depending 
on pre-dose 
testosterone 
levels 
0002-1975-90 
Pump containing 60 
actuations 
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